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Abstract
Measurement of the diffusing capacity of the lung is part of the routine
pulmonary function assessment in every patient and the single breath method is the
most commonly used method. This method requires a subject to inspire a gas mixture
followed by a 10 second (s) breath-hold. However dyspnoea may preclude measurement
in patients with advanced pulmonary disease. We sought to determine if breath-hold
time reduction had a significant effect on measured DLco values.
Forced spirometry and CO-diffusion by the single breath method were
performed by a respiratory scientist with a Jaeger master-screen PFT equipment, in
duplicate with breath-holding of 10 , 8 and 6 s in 30 control subjects (FEV1 107 ±
12.04% predicted), 30 severe COPD patients (FEV1 37.2 ± 7.92% predicted), and 30
patients with interstitial lung disease (ILD) (FEV1 69.5 ± 17.61% predicted).
There was no significant difference between DLcoSB and KCO measured at 10,
8 and 6 s in the control group (p=0.4431) and ILD group (p=0.5915). However, there
was a significant difference between DLcoSB (p=0.0003) and DLco (VA) (p=0.0183)
measured at 10, 8 and 6 s in the COPD group. In the presence of severe airway
obstruction the DLco decreases with breath-hold time reduction.
In the control group and patients with ILD, there was no significant change in
the DLcoSB when breath-hold time was reduced from 10 to 6 s. This could allow a
reduction in breath-hold time when measuring the DLco in patients with advanced ILD
who are unable to breath-hold for 10 s, but not in patients with severe COPD.
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Definitions
Anti-cholinergic: antagonist of acetylcholine drug and other muscarinic agonists. It
blocks the muscarinic action of acetylcholine at receptors on postsynaptic membranes,
and inhibits the response by postganglionic parasympathetic nerve activation. (Gross,
1993)

Asthma: pulmonary obstructive disease with increased responsiveness of the airways to
different stimuli which produces an inflammation and widespread narrowing of the
airways. It changes in severity, either spontaneously or as a result of treatment. (West,
2008b)

Β2Agonist: bronchodilator drug that combines with β2 receptors in the lung and relax
the smooth airway muscle by increasing the adenyl cyclase activity. (West, 2008b)

Bronchitis: pulmonary obstructive disease with typical excessive mucus production in
the bronchial tree and sputum expectoration. (West, 2008b)

Bronchodilators: drugs that reverse or prevent the broncho-constriction of the lung.
(West, 2008b)

Calibration: procedure that allows establishing the relationship between sensordetermined values of flow or volume and the actual flow or volume. (Brusasco et al.,
2005)
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CD4 helper phenotype: helper T cell with glycoprotein CD4 on the surface and
therefore, called T4 cells. (Ganong, 1995)

Capacity: composed of two or more volumes. (West, 2008a)

Cystic Fibrosis: a genetic disease affecting the function of all exocrine glands with
abnormal chloride and sodium transport. (West, 2008b)

Diffusion: process by which a gas or a substance in solution expands, because of the
motion of its particles into or out of an area in which it is present in high concentration,
to fill all of the available volume. (Ganong, 1995)

Dyspnoea: difficulty with breathing sensation. (West, 2008b)

Emphysema: pulmonary obstructive disorder with typical enlargement of the air spaces
distal to the terminal bronchiole and destruction of their walls. (West, 2008b)

Fibroblasts: synthesizer cell of collagen and elastine, which are the main components of
the interstitium in the alveolar wall.

Fick’s law: “The amount of gas that moves across a sheet of tissue is proportional to the
area of the sheet but inversely proportional to its thickness”. West (2008a)

Hypoxemia: deficiency of O2 at the body tissue level. (Ganong, 1995)

8

Inflammatory response: localized and complex response to a foreign substance or in
some situations to substances produced internally. (Ganong, 1995)

Interstitium: space filled between the alveolar epithelium and the capillary endothelium.
(West, 2008a)

Lymphocytes: white blood cell, 2 cell type usually present in peripheral blood. (Ganong,
1995)

Methylxanthines: drug with bronchoactive and slight anti-inflammatory properties, only
around one-fourth as potent as β2-agonists. (West, 2008b)

Mitochondria: cell generating power units greater and more developed where energy
requiring processes occurs. (Ganong, 1995)

Obstructive pulmonary disorder: unbalanced reduction of the maximal airflow from the
lung in relation to the maximal volume, leading to airway narrowing during expiration
and is defined by an FEV1/FVC ratio reduction below the 5th percentile of the
predicted value. (Brusasco et al., 2005)

Pulmonary Hypertension: sustained elevation of the pulmonary arterial blood pressure.
(Ganong, 1995)

Non-Obstructive Pulmonary disorder: ventilatory disorder defined by a TLC reduction
below the 5th percentile of the predicted value, and a normal FEV1/FVC ratio.
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Shunt: blood that enters the arterial system without passing ventilated areas of the lung.
(West, 2008a)

Spirometry: method used to measure lung volume changes during a forced breathing
maneuver. The FVC maneuver is the most frequently performed, in which a subject
inspires maximally and then expires as rapidly and completely possible. (Hyatt et al.,
2003)

Vasoconstriction: constriction of the resistance vessels. (Ganong, 1995)

Ventilation: process by the air is forced to get inside the lungs, from the airways to the
alveoli, from where, after releasing the O2, returns saturated of CO2 being released to
the atmosphere. (West, 2008a)
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Glossary
ATS – American Thoracic Society
Β – Beta
BMI – Body Mass Index
C – Centigrade
CaO2 – O2 concentration in the arterial blood
CH4 – Methane
cm – Centimetres
CO – Carbon Monoxide
COHb – Carboxyhaemoglobin
COPD – Chronic Obstructive Pulmonary Disease
CO2 – Carbon Dioxide
CvO2 – O2 concentration on the mixed venous blood
dl – Decilitre
DLco – Lung diffusing capacity for carbon monoxide
DLcoSB – Lung diffusing capacity for carbon monoxide by the Single breath Method
DM – Membrane conductivity
e – Electron
ECCS – European Community for Coal and Steel
Eqt – Equation
ERS – European Respiratory Society
ERV – Expiratory Reserve Volume
ESP – Epidemiologic Standardization Project
F – Female
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FAco – Fraction of CO in alveolar gas
FACO0 – Fraction of CO in alveolar gas at the beginning of the breath-hold,
FACOT – Fraction of CO in alveolar gas at the end of breath-hold.
FACO2 – Fractional concentration of CO in the alveolar gas
FAHe – Fraction of He in alveolar gas
(fb) – Frequency
FEV1 – Forced Expiratory Volume on the first second
FICO – Fraction of CO in the reservoir (usually 0.003)
Fig – Figure
FIHe – Fraction of He in the inspired gas (usually 0.10).
FIVC – Forced Inspiratory Vital Capacity
FRC – Functional Residual Capacity
FVC – Forced Vital Capacity
g – Gram
H – Hydrogen
H2O – Water
Hb – Haemoglobin
He – Helium
Hg – mercury
IC – Inspiratory Capacity
IL - Interleukin
ILD – Interstitial Lung Disease
IPF – Idiopathic Pulmonary Fibrosis
IR – Infra- Red
IRV – Inspiratory Reserve Volume
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K – Diffusion coefficient
KCO – Transfer factor for CO
Kg – Kilogram
kPa – Kilopascals
L – Litre
Ln – Natural logarithm
M – Male
m2 – Square meter
min – Minute
MMEF – Maximum mid-expiratory flow
ml – Millilitre
mm – Millimetres
mmol – Millimol
ms – Millisecond
N2 – Nitrogen
O2 – Oxygen
P – Pressure
PaCO2 – Partial pressure of CO2 in the arterial blood
PACO2 – Alveolar O2 pressure
PaO2 – Partial pressure of O2 in the arterial blood
PB – Barometric Pressure
Pco – CO pressure
PCO2 – Partial pressure of CO2
PO2 – Partial pressure of O2
PECO2 – Expired CO2 pressure
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Pred – Predicted
Q – Blood flow per unit time
R – Respiratory exchange ratio
RV – Residual Volume
s – Seconds
SD – Standard Deviation
STPD – Standard temperature (273 K, 00C), pressure (101.3 kPa, 760 mmHg) and dry
T – Breath-hold interval
Th0 - The T-lymphocytes
Th1 - T-helper type 1 cells
Vc (theta) – Reaction rate (specific uptake of CO by the blood)
TLC – Total Lung Capacity
VA – Alveolar Volume
VA – Alveolar ventilation
VA/Q – Ratio of ventilation to blood flow
VC – Vital Capacity
Vc – Pulmonary capillary blood volume
VD – Dead space
VD/VT – Ratio of dead space to tidal volume
VE – Ventilation
V/Q – Ventilation/Perfusion ratio
VT – Tidal Volume
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Background
The human respiratory system is made up of gas exchanging organs which are
the lungs and a pump that ventilates the lungs. The pump consists of the chest wall, the
respiratory muscles (which increase and decrease the size of the thoracic cavity), areas
in the brain that control these respiratory muscles and the tracts and nerves that connect
the brain to the muscles. The respiration of a subject can be assessed by pulmonary
function testing, described as the process of having a subject performing specific
inspiratory and expiratory manoeuvres while breathing in and out of tubing attached to
equipment that measures a variety of variables. These tests allow the evaluation of the
respiration of a subject and assessment of any abnormality, as well as to quantify it.
There are a wide range of pulmonary function tests measuring lung volumes, gas
exchange in the lungs or evaluating respiratory muscle function.
Pulmonary function tests are designed to identify and quantify defects and
abnormalities in the function of the respiratory system. They can answer questions like
how badly impaired is the patient lung function, if a patient has impaired gas exchange
in the lung or if a treatment is of benefit. Although the majority of these procedures are
non-invasive, they require cooperation from the subject and expertise from the
respiratory technician. Measurement of the diffusing capacity of the lung involves the
subject inhaling a low concentration of carbon monoxide (CO) and a tracer gas to
determine gas exchange within the lung. Several methods of evaluating CO diffusion
are available, but the single breath technique (DLcoSB) is the most commonly used.
This method is called the single breath technique because the CO diffusion in the human
lung is measured during a 10 seconds (s) breath-hold by a subject.
15

The main disadvantage of the single breath method is that not every subject is
able to hold their breath for 10 s in order to measure lung diffusion. Shortening breathhold time might allow for completion of the test in subjects with more severe
respiratory impairment as clinical experience shows that longer breath-hold times lead
to difficulties in cooperation in many patients. Based on limited published data on the
effect of breath-hold time reduction in lung diffusion measurement, we decided to
investigate if the values obtained with a shorter breath-hold time are significantly
different from conventional measurements to assess human lung diffusion capacity.
This study will investigate if the reduction of breath-hold time in the
single-breath CO diffusion measurement has a significant effect on measured DLcoSB
in healthy subjects, patients with severe chronic obstructive pulmonary disease (COPD)
and patients with interstitial lung disease compared with conventional measurements.
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Chapter 1

INTRODUCTION

1.1 Aim of the Study

We sought to determine if breath-hold time reduction in the single-breath CO
diffusion measurement has a significant effect on measured DLcoSB values in control
group, patients with severe chronic obstructive pulmonary disease (COPD) and patients
with interstitial lung disease (sarcoidosis with interstitial fibrosis or idiopathic
pulmonary fibrosis (IPF)) compared with conventional measurement using ATS/ERS
standards. Demonstration of theb absence of a significant difference associated with
breath-hold time reduction can potentially lead to a change in guidelines for breath-hold
time during DLcoSB measurements and can thus increase the number of patients in
whom DLcoSB can be measured, particularly for those who are unable to breath-hold
for 10 s.

1.2 Anatomy and Physiology of the Lung

The airways of the lungs consist of a series of branching tubes which become
narrower, shorter and more numerous as they penetrate deeper into the lung. Their
function is to lead inspired air to the gas exchanging regions of the lung. The trachea
divides into right and left main bronchi which in turn divide into lobar, then segmental
bronchi, down to the terminal bronchioles. The bronchioles are the smallest airways
17

making up the conducting airways with no alveoli and therefore constitute the anatomic
dead space of the lung, where no gas exchange occurs. The terminal bronchioles divide
into respiratory bronchioles which lead to the alveolar ducts and alveoli where gas
exchange occurs. This area is known as the respiratory zone of the lung and accounts for
2.5-3 L of volume during rest.
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Fig. 1.1
Idealization of the human airways according to Weibel (1963),
accessed 2 April 2012, http://www.comprehensivephysiology.com
The figure shows a model of the human airway system divided by generations of symmetric
branching from trachea (0) to acinar airways (15–23), ending in alveolar sacs. The first 16
generations make up the conducting airways, and the last 7, the respiratory zone (or the
transitional and respiratory zones).
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The airways systematically divide over an average of 23 generations of
dichotomous branching, as described by Weibel (1963), ending eventually in a blind sac
(figure 1.1). The last nine generations of these airways are connected to tightly packed
alveoli, airways chambers in which gas exchange takes place, whereas the central
airways serve the function of conducting the air to the gas-exchange parenchyma.
According to Fishman (2007), the gas exchange parenchyma can be divided in
two units: the lobes and the acini. There are three lobes on the right (upper, middle and
lower) and two on the left (upper and lower), which are separated by the pleura. The
acini begin with a transitional bronchiole and terminate with alveoli and are defined as
parenchymal units which and participate in gas exchange.
The main mechanism of ventilation in the respiratory zone, illustrated in figure
1.2, is the diffusion of respiratory gases and the rate of diffusion of gas molecules within
the airways is so rapid, as well the distances to be covered so short, that “differences in
concentration are virtually abolished within a second”. (West, 2008a)
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Fig 1.2
Gas diffusion in the alveolar-capillary membrane,
accessed 2 April 2012, http://medical.tpub.com/10669-c/css/10669-c_56.htm
The alveoli are thin, microscopic air sacs within the lungs, in direct contact with
the pulmonary capillaries. At this level the gas exchanges occurs in the lung.

The pulmonary blood vessels show a characteristic relationship to these
structural respiratory units, following the airway course through the centre of the units
and finally ending in the capillaries located in the alveolar septa of lung parenchyma.
This pulmonary blood vessels form a series of branching tubes from the pulmonary
21

artery into the capillaries and back to the pulmonary veins. As shown in figure 1.3, the
pulmonary capillaries form a dense network around the alveoli, allowing for efficient
gas exchange. (West, 2008a)

Fig. 1.3
Pulmonary Circulation stratification,
accessed 04 April 2012, http://www.78steps.com,

The blood is pumped from the heart right ventricle, it enters the pulmonary artery. This
artery splits and takes blood to each lung. In the lungs, the blood passes through sacs
called alveoli where gas exchange occurs.
22

Airflow occurs both by mass flow (laminar, turbulent or transitional airflow) and
by diffusion. Mass flow occurs in the larger airways whilst diffusion occurs in the
alveolar ducts and sacs. As the cross-sectional area of the airways increases, the velocity
of the airflow decreases.

1.3 Measurement of Lung Volumes and gas exchange of the Lung

1.3.1 Static and Dynamic Lung Volumes

Static lung volumes and capacities (composed of two or more volumes) are an
excellent tool to assess human lung function. The total lung capacity (TLC) is the
maximum volume of air in the lungs after a maximal inspiratory effort. The volume of
air that remains in the lungs after maximal expiration (the residual volume (RV)) cannot
be measured directly.
Volume between TLC and RV, the vital capacity (VC), can be measured directly
as can other volumes like the expiratory reserve volume (ERV) and inspiratory reserve
volume (IRV). The tidal volume (VT) and IRV will constitute the inspiratory capacity
(IC), which also is the difference between the TLC and the functional residual capacity
(FRC). The FRC is the volume of air remaining at the end of a normal tidal expiration.
(Cooper et al., 2011)
Figure 1.4 illustrates the different static volumes and capacities of the lung.
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Fig. 1.4
Scheme of static lung volumes and capacities,
accessed 4 April 2012, http://www.cybermedicine2000.com,
The diagram shows the changes in volume (on the vertical axis) against time (on the horizontal
axis) as a subject breathes, initially tidal volumes, and then inspires and expires maximally.

When changes in volume or flow with respect to time are recorded, dynamic
volumes are obtained. If a subject takes a maximal breath to TLC exhaling forcibly to
RV and then inhales back to TLC, the forced vital capacity (FVC) and forced inspiratory
vital capacity (FIVC) can be measured during the expiratory and inspiratory
manoeuvres respectively. A series of variables can be obtained from this recording with
respect to time, the most valuable of which is the forced expiratory volume in the first
second (FEV1). It has been reported by Cooper et al. (2011) that “on average a normal
subject can exhale about 80% or more of the FVC in the first second of a full
exhalation”. They also suggest that the measurement of the FEV1 and FVC has a
number of applications, such as determining if lung disease is present and quantifying
the degree of impairment.
24

Lung volumes can be measured and recorded directly using a volume measuring
spirometer which electronically reproduces the volume signal with respect to time to
obtain the flow, allowing the construction of volume-time and flow-volume curves as
illustrated in figure 1.5.

Fig. 1.5
Volume-time and flow-volume loop,
accessed 4 April 2012, http://blog.ert.com/2011/04/29/spirometry
Spirometry is one diagnostic test for pulmonary mechanics, which measures the inhalation and
exhalation of air over time and represented by spirograms: flow volume loop (A) and volume
time curve (B).

The flow-volume curves are measured directly using a flow measuring
pneumotachograph and the shape of the flow volume curve assists in the recognition of
different types of respiratory impairment.
Before performing pulmonary function tests the patient’s age, height, weight and
sex must be obtained for the calculation of reference values, as lung volumes are related
25

to body size, with height as a major correlating factor. Reference equations for
spirometry are obtained from cross-sectional studies and both the European Community
for Coal and Steel (ECCS) and the American Thoracic Society (ATS) have published
reference equations for spirometry. (Brusaco et al., 2005) Combined reference equations
published by Quanjer et al. (1993) are often used in Europe for people aged 18-70 years
old, with a height range of 155-195 cm in males and 145-180 cm in females.

1.3.2 Ventilation

Ventilation (VE) is the process by which air is drawn into the lungs and gas from the
alveoli is expelled, allowing gas exchange. In this process, oxygen (O2) is absorbed in
the pulmonary circulation and carbon dioxide (CO2) released from the blood into the
alveoli. The primary function of ventilation is to facilitate gas exchange. VE is the
movement of air between the atmosphere and the alveoli and can be calculated from
breathing frequency (fb) and VT using the equation:

Eqt. 1.1 From Cooper et al., 2011.

The total volume of air breathed by a subject per minute and the portion of
volume that reaches the alveoli, called alveolar ventilation, must be differentiated.
Alveolar ventilation (VA) is the volume of gas that effectively participates in gas
exchange and is always less than total ventilation. The anatomical dead space, which is
the volume of air in the conducting airways that does not participate in gas exchange,
represents the difference between total and alveolar ventilation. (Cooper et al., 2011)
The lung volume that is ventilated but not perfused by pulmonary capillary
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blood flow constitutes the respiratory dead space (VD) and can be divided into: the
conducting airways (anatomic dead space) and the non-perfused alveoli (alveolar dead
space). The total volume of air breathed by a subject per minute (total ventilation) can
be measured directly by having the subject breathing through a valve box that separates
the inspired from the expired gas, and collects all the expired gas in a bag. (Ruppel,
1994)
However, the VA cannot be measured directly and one method to determine is by
measuring the volume of the anatomic dead space and calculates the dead space
ventilation using the following equation 1.2:

Eqt 1.2 From Ruppel, 1994.

In atmospheric gas, the CO2 concentration is almost zero, so the VA can be
calculated also based on CO2 elimination from the lungs. In this method, a volume of
expired gas is collected in a bag and analysed to determine the volume of CO2 and VA
calculated by the following equation:

Eqt. 1.3 From Ruppel, 1994.

In equation 1.3 the VCO2 is the volume of CO2 produced in litres per minute and
the FACO2 is the fractional concentration of CO in alveolar gas.
The volume of air in the conducting airways that does not participate in gas
exchange is called anatomic dead space, usually approximately 150 ml that can be
increased by large inspirations due to the traction or pull exerted on the bronchi by the
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surrounding lung parenchyma. This anatomic dead space can also depend on the size
and posture of the subject. One of the methods used to measure VD is the Fowler’s
method, where a subject breaths a nitrogen concentration following a single inspiration
of oxygen (West, 2008a) as shown in fig 1.6.

Fig 1.6
Fowler’s method,
accessed 4 April 2012, http://www.tzhealth.com,
The figure shows a N2 analyzer monitoring continuously the N2 concentration of gas being
inspired or expired. During inspiration, the N2 analyzer records 80% N2 in inspired and expired
gas. The subject will take a deep breath of O2 and followed by a slow breathe out. During
inspiration, the N2 analyzer records 0% N2. At the beginning of expiration, about 50 ml of pure
O2 is expired (phase I). In phase II about 200 to 300 ml of N2 concentration rises, which
represents the washout of the remainder of the dead space gas by alveolar gas, and then at last
by pure alveolar gas (phase III). At phase IV, the N2 concentration of the expiration end rises
because of the progressive closure of the small airways at the bases of the lungs.
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The principal of this method is to measure volume in the conducting airways
until dilution of inspired gas occurs with gas already in the lung. The volume measured
will depend on the geometry of the rapidly expanding airways, reflecting the
morphology of the lung airways.
Another way of measuring the dead space is the Bohr’s method using the
Bohr’s equation (Eqt. 1.4). Since the expired CO2 comes mainly from alveolar gas and
not from dead space and also because the alveolar concentration of CO2 is difficult to
determine, the partial pressure is used and the equation 1.4 is written as follows:

Eqt. 1.4 From Cooper et al., 2011.

In equation 1.4, A and E refer to alveolar and mixed expired, respectively. The
normal ratio of dead space to tidal volume (VD/VT) is from 0.2 to 0.35 at rest.
According to Ruppel (1998) this method measures the volume of the lung that
does not expel CO2 and the volume measured is called physiologic dead space. In
normal subjects the anatomic and physiological dead space are almost the same but in
patients with pulmonary impairment, the physiological dead space may be larger
because of ventilation / perfusion mismatch in the lung. Therefore, the measurement of
physiological dead space represents a useful index of ventilation-perfusion in the lung
since all CO2 in expired gas comes from perfused alveoli. The VD/VT ratio will reflect
the volume of ventilation not used in the conducting airways and poorly perfused
alveoli. The VD measurement provides important information regarding the ventilationperfusion characteristics of the lungs, increasing with increased VT during exercise and
decreasing with bronchial obstruction or mucous plugging. West (2008) states: “lower
29

regions of the lung are better ventilated than the upper regions because of the effects of
gravity on the lung”.

1.3.3 Perfusion

The pulmonary circulation begins with the pulmonary artery, which collects
mixed venous blood from the right ventricle. The pulmonary artery branches
successively like the bronchial tree into the pulmonary arteries and arterioles following
the airways to the terminal bronchioles. These arterioles supply the capillary network in
the walls of the alveoli, forming a dense network in the alveolar wall as illustrated in
figure 1.7 and establishing an efficient surface for gas exchange.
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Fig. 1.7
Alveolar circulation,
accessed 4 April 2012, http://www.uic.edu,
The bronchi branch into smaller tubes called the bronchioles and then to small gas exchange
units know as alveoli, covered by the smallest blood vessels, the capillaries.

Oxygenated blood is collected from the capillaries by small pulmonary veins
that will unite to form four large veins that drain into the left atrium of the heart. The
pulmonary circulation pressure is much lower compared with the systemic circulation.
The systemic circulation is responsible for the supply of blood to various body organs
and by contrast the pulmonary circulation accepts the entire cardiac output. The
pressure at the pulmonary capillaries is unknown as they are surrounded by gas and they
collapse or distend depending on the pressures within and around them. The pressure
31

difference between the inside and outside of the capillaries is called the transmural
pressure.
During inspiration when the lungs expand, larger blood vessels like the
pulmonary arteries and veins are pulled open by radial traction of the elastic lung
parenchyma decreasing the pressure around them. Alveolar capillaries are exposed to
alveolar pressure and their calibre is determined by the relationship between alveolar
pressure and the pressure within them. (West, 2008a)
The extra-alveolar vessels include all the blood vessels that run through the lung
parenchyma. These vessels are exposed to a lower pressure compared to the alveolar
pressure and are pulled by the radial traction of the surrounding parenchyma of their
walls. The lung volume constitutes an important determinant of pulmonary resistance.
During deep inspiration, alveolar pressure rises compared to capillary pressure and the
blood vessels will be compressed and therefore their resistance rises. Also the calibre of
these pulmonary capillaries will depend on lung volume, decreasing at larger lung
volumes due to stretching and thinning of the alveolar walls.
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Fig. 1.8
Four zone model of pulmonary circulation,
accessed 4 April 2012, http://www.coheadquarters.com
The human lung is about 30 cm tall from apex to base therefore gravity exerts an important role
in determining blood flow direction in the lung. The human lung can be divided into 4 zones
represented by the figure 1.8 above. The hydrostatic arterial and venous pressures fall with
increasing distances up the 30 cm height of the lung where: a=arterial, A=alveolar and
V=venous.

The lung of an adult is around 30 cm from apex to base and gravity is a
significant factor in determining blood flow in the lung. The lung can be divided into 4
zones of perfusion as shown in figure 1.8, illustrating that the hydrostatic blood pressure
is highest at the base and lower at the apex.
The four zone model presented in figure 1.8 shows that the arterial and venous
pressures at the apex may both be less than the air pressure inside the alveoli and this
will interrupt the blood flow as the air pressure decreases and closes the blood vessels.
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Often, there is very little, if any, blood flow in zone 1. At zone 2, the arterial pressure is
higher than alveolar pressure but the venous pressure is less than alveolar pressure and
the blood flow, instead of being determined by the usual arterial-venous pressure
difference, is determined by the arterial-alveolar gradient. Arterial pressure increases in
zone 2 due to gravity, while alveolar pressure remains relatively constant and so the
arterial-alveolar difference increases in zone 2 and thus blood flow increases from the
top to the bottom of this zone.
In zone 3, the arterial and venous pressures exceed alveolar pressures and here
blood flow will be determined by the arterial-venous difference. In this zone of the lung,
both arterial and venous pressure increase due to gravity and the pulmonary blood
vessels distend leading to decreased resistance. Also the pulmonary blood flow will rise
from the top to the bottom of zone 3.
Finally, at zone 4 at the base of the lung, the ratio of ventilation to blood flow is
low and consequent alveolar hypoxia leads to compensatory vasoconstriction, limiting
local blood flow. When the alveolar pO2 is reduced, hypoxic pulmonary
vasoconstriction occurs through contraction of smooth muscle in the walls of small
pulmonary arterioles. The primary function of hypoxic pulmonary vasoconstriction is to
direct blood flow away from hypoxic regions of the lung. These hypoxic regions may
arise from airway obstruction and this diversion of blood flow reduces the effects on gas
exchange. West (2008a)
According to West (2008a) this mechanism remains obscure in spite of a great
deal of research.
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1.3.4 Ventilation – Perfusion

The relationship between ventilation and blood flow is a major determinant of
pulmonary gas exchange. The four scenarios of impairment of gas exchange that result
in hypoxemia are: hypoventilation, diffusion impairment, shunt and ventilationperfusion mismatch. West (2008b) defines hypoxemia as an abnormally low pO2 in
arterial blood, with the normal value between 11 and 13 kPa. The pO2 in the alveolar
gas depends on a balance between two processes: pulmonary capillary blood capacity
for the O2 absorption and its continued replacement by alveolar ventilation. The rate at
which O2 is absorbed from the lung is determined by its consumption by the body
tissues and is almost constant at rest. Alveolar pO2 is greatly determined by the level of
alveolar ventilation. If alveolar ventilation is decreased, the alveolar pO2 decreases and
the pCO2 increase due to hypoventilation. If hypoventilation is present, the pCO2
increases until a steady state has been achieved and the alveolar and arterial PO2
decreases, except when the subject breaths an O2 mixture that compensates for reduced
ventilation. (West, 2008b)
Diffusion impairment means that the pO2 in the pulmonary capillary blood and
alveolar gas are not balanced. In some pulmonary diseases, the alveolar-capillary
membrane is thickened and diffusion is decreased to the point that equilibration may be
incomplete, due to a slower time course for diffusion. The presence of pulmonary
diseases, such as interstitial lung diseases where the diffusion path from alveolar gas to
red blood cell may be increased, may be affect time for oxygenation. (West, 2008b)
Another factor that can decrease the arterial pO2 in relation to alveolar level is the
presence of shunted blood. According to West (2008) shunt refers to blood that enters
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the arterial system without being previously in ventilated areas of the lung.
Intrapulmonary shunts can be caused as well by arterial-venous malformations, often
with genetic basis. The hypoxemia induced by a shunt cannot be corrected by
administering 100% O2 because according to West (2008b) “the shunted blood that
bypasses ventilated alveoli is never exposed to the higher alveolar pO2, so it continues
to depress the arterial pO2”.
The intrapulmonary shunts can be divided in true shunt and shunt-like effect. In
a true shunt, blood flows from the right to the left side of the heart without contacting an
alveolus for gas exchange (perfusion without ventilation). A true shunt can be classified
as an anatomic or a capillary shunt and the main difference is their origin. Anatomic
shunts can be normal when the shunted blood comes from veins such as bronchial,
pleural, or thebesian veins, and abnormal when shunted blood arises from congenital
heart disease, pulmonary arteriovenous malformations or vascular lung tumours.
Capillary shunts are caused by alveolar collapse (atelectasis), alveolar fluid
accumulation (pulmonary oedema) and alveolar consolidation (pneumonia). As
anatomic and capillary shunts are true shunts, the associated hypoxia cannot be treated
by increasing the inspired O2 concentration.
In the shunt-like effect, the blood exchanges gas with alveolar gas but the pO2
does not reach the pO2 of normal alveoli. This type of shunt can be caused by
hypoventilation (bronchospasm or excessive mucus in the tracheobronchial tree) and
alveolar-capillary membrane impairment such as in patients with pulmonary fibrosis,
where diffusion does not have enough time to occur.
The ventilation-perfusion inequality is characterized by mismatch of ventilation
and blood flow in various regions of the lung leading to an impaired gas transfer. In this
process, both O2 and CO2 transfer results will be impaired and this is the main
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mechanism of hypoxemia in diseases such as chronic obstructive pulmonary disease,
interstitial lung disease and vascular disorders. The ventilation-perfusion inequality is
commonly identified by excluding the other three causes: hypoventilation, diffusion
impairment and shunt. (West, 2008b)
The O2 concentration in the human lung is determined by the ratio of ventilation
to blood flow (VA/Q) by the following equation (which also applies to CO2, N2 and any
other gas present under steady-state condition). The equation is as follows:

Eqt. 1.5 From Cooper et al., 2003.

Where:
•

Q is the blood flow per unit time,

•

R is the respiratory exchange ratio,

•

CaO2 the O2 concentration in the arterial blood,

•

CvO2 the O2 concentration on the mixed venous blood,

•

PaCO2 the partial pressure of CO2 in the arterial blood.

If the VA/Q of the lung unit is decreased by airway obstruction, the O2
concentration will decrease and the CO2 will rise, and if the ventilation is completely
ceased, this ratio will reach zero. On the other hand, if this ratio increases by impaired
perfusion, the O2 concentration will increase and the CO2 will fall, and also if the blood
flow ceases, will reach the composition of the inspired gas.
Regional gas exchange patterns are defined by the VA/Q, being high at the apex
of the lung and much lower at the base. If pulmonary disease is present, this regional
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pattern will disappear and at the alveolar level the normal relationships between
ventilation and blood flow will be perturbed. Although ventilation-perfusion inequality
will reduce the gas exchange efficiency of the lung for all gases, in many cases a normal
pCO2 may occur because ventilation will be increased in the alveoli. However, the pO2
is always low and so the alveolar-arterial pO2 difference is a useful measure of
ventilation-perfusion inequality. (West, 2008b)

1.3.5 Diffusion Capacity of the Lung

Oxygen travels along the airways from the mouth into the alveoli by bulk
movement of air (movement of air from a region of high pressure to one of low
pressure) and diffusion occurs by movement of a gas when a pressure gradient in the
alveoli is present. Diffusion of gases in the lung occurs by molecular movement that
increases as temperature rises and occurs over a short distance of about 1mm, between
the alveolar duct and the alveolar capillary membrane. (Cooper et al., 2011) The O2
must cross the alveolar capillary membrane before entering the erythrocytes, moving
from the gas phase to the liquid phase. Oxygen has to diffuse through pulmonary
surfactant, the alveolar epithelium, the interstitium, the capillary endothelium and then
the plasma before reaching the erythrocyte membrane and finally combining with
haemoglobin. The blood will carry O2 to the body tissues where it diffuses through the
plasma, capillary endothelium, interstitium and the mitochondrial membrane. The
reverse process will occur for CO2. (Cooper et al., 2011) According to West (2008a)
“the diffusion of a substance in fluids (liquids or gases) is a passive process occurring
between regions of differing gases concentrations. If a membrane of constant thickness
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and permeable to a particular gas is placed between two fluid compartments, the
diffusion of a gas across the membrane is described by Fick’s law of diffusion which
states that the rate of transfer of a gas through a sheet of tissue is proportional to the
tissue area and the difference in gas partial pressure between the two sides, and
inversely proportional to the tissue thickness” (West, 2008a). The following equation
1.6 is Fick’s Law of diffusion and allows the calculation of the diffusion of a gas.

Eqt. 1.6 From Cooper et al., 2011.

In the equation 1.6, K is the diffusion coefficient and P1 – P2 the difference of
the gas partial pressure. The larger the surface area (A), the higher will be the difference
in pressure and the thinner the membrane (t), the higher will be the rate of diffusion as
illustrated in figure 1.9.
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Fig. 1.9 Fick’s law of diffusion,
accessed 4 April 2012, http://www.elu.sgul.ac.uk
The O2 diffuses from a place of higher partial pressure (P1O2, e.g. the alveolar air) to one of
lower partial pressure (P2O2, e.g. the pulmonary capillary) through a membrane of area A and
thickness X.

The density and solubility of a gas will also determine the diffusion rate.
Oxygen, which is less dense than CO2, diffuses about 1.2 times faster under same
conditions in the alveoli. However, their relative solubility changes when crossing the
alveolar-capillary membrane, as CO2 in the liquid phase is about 24 times more soluble
than O2, and therefore CO2 diffuses about 19 times faster than O2. (Cooper et al., 2011)
Oxygen travels easily across the alveolar capillary membrane combining with
haemoglobin (Hb). Initially, this movement will depend on a pressure gradient between
alveoli and capillaries for O2 which continues to diffuse from alveoli to capillary blood
until Hb becomes saturated with O2. At this point the O2 pressure rises and equilibrates
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with alveolar O2 pressure (PAO2). If the thickness of the alveolar-capillary membrane
increases, O2 diffusion is impaired and the rate of rise of oxygen partial pressure (pO2)
is reduced. If a severe abnormality is present, the pO2 may not reach the pO2 of alveolar
gas. (Cooper et al., 2011) The rate of diffusion will therefore depend of the physical
properties of the alveolar-capillary membrane, as the surface area and thickness of the
membrane will determine the rate of diffusion. The surface area for diffusion can be
altered by changes in lung volume and in pulmonary artery pressure.
The Hb molecule has a major role on the gas transport and diffusion given its
large capacity for O2, as each Hb molecule can transport four O2 molecules, releasing
O2 when needed. Hb is also involved in CO2 and hydrogen ion transport. The
combination of O2 with Hb can be illustrated by the Oxyhaemoglobin dissociation curve
in figure 1.10 and is only possible due to changes in the structure of the Hb molecule.
(Cooper et al., 2011)
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Fig. 1.10
Oxyhaemoglobin dissociation curve
From Cooper et al., 2011
The Oxyhaemoglobin dissociation curve is a graph that shows the percent saturation of Hb
various partial pressures of O2. The main goal of the dissociation curve is to show the
equilibrium of oxyhaemoglobin and nonbonded Hb at various partial pressures. At high partial
pressures of O2, Hb binds to O2 to form oxyhaemoglobin.

The sigmoidal shape of the Oxyhaemoglobin dissociation curve is the result of
chemical reactions that occur between O2 and each haem group of the Hb molecule.
This curve shifts position but the sigmoid shape is preserved. (Cooper et al., 2011)
Figure 1.10 illustrates the percentage of haemoglobin that reacts with O2 at each
O2 pressure. Oxygen rapidly combines with haemoglobin as the pO2 rises but around 60
mmHg, despite of increase of pO2 there is minimal increase in the oxygen-haemoglobin
binding as Hb is already 90% saturated. At the flat portion of this curve, the pO2 in the
blood can drop from 100 to 60 mm Hg and the Hb will remain 90% saturated with O2
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and wide changes in pO2 only will produce a small variation in the oxygen saturation
(SaO2). Even after most of the O2 is transferred, significant partial pressure difference
appears to exist between the alveolar gas and the blood, as blood continues to flow
through the alveolar-capillary system which facilitates O2 diffusion across the alveolarcapillary membrane.
There are other factors that will shift the O2 dissociation curve. If the pH
decreases this curve will shift to the right (decreased affinity) caused by a rise of pCO2
as CO2 moves into the blood from the cells, helping the unloading of O2. In the opposite
scenario, an increase of pH will shift the curve to the left (increased affinity), caused by
decreased pCO2 as CO2 moves from the blood into the alveoli, increasing the loading of
O2 in the lungs and decreasing the unloading of O2 at the tissues. Temperature is another
important factor affecting binding of the O2 with the Hb. An increase in temperature
will shift the curve to the right (decreased affinity), enhancing the unloading of O2 and
decreasing the loading of O2 in the lungs. In the other hand, a decrease in temperature
will shift the curve to the left (increased affinity), increasing the loading of O2 in the
lungs.
The CO2 concentration in the blood will also affect the Oxyhaemoglobin
dissociation curve. An increase in CO2 will shift the curve to the right (decreased
affinity) because an increase of the partial pressure of arterial carbon dioxide (PaCO2)
leads to an increase in hydrogen ion concentration. This will enhance the unloading of
O2 in actively metabolizing tissues like muscles during exercise and decrease loading of
O2 in the lungs. A decreased CO2 will shift the curve to the left (increased affinity),
caused by decreased pCO2 as CO2 moves from the blood into the alveoli, as well as
enhancing the loading of O2 in the lungs and reducing the unloading of O2 at the tissues.
Finally the 2,3-Diphosphoglycerate (2,3-DPG), a substance that is formed by the red
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blood cells during anaerobic glycolysis will shift the curve to the right (decreased
affinity) if its concentration rises, as O2 will be released more efficiently at the tissues.
This scenario can be caused by hypoxia, anaemia and pH increase. On the other hand,
decreased 2,3-DPG will shift the curve to the left (increased affinity), enhancing the
loading of O2 in the lungs and decreasing the unloading of O2 at the tissues.
The diffusing capacity of the lung is measured using carbon monoxide (CO) and
referred to as DLco. The DLco is used to assess the lungs gas exchange, measuring the
transfer of CO across the alveolar-capillary membrane. The CO affinity to bond with Hb
is approximately 210 times more than O2 and with normal Hb concentration and normal
ventilatory function, the major limiting factor to CO diffusion is the integrity of the
alveolar-capillary membrane. CO concentration in pulmonary capillary blood is
normally very low or inexistent and therefore the pressure gradient causing diffusion is
effectively the alveolar pressure. Consequently, a small amount of CO in inspired gas
will produce changes in the concentration of inspired versus expired gas that can be
measured and if the partial pressure of CO in the alveoli and the rate of uptake of the
gas can be measured, the DLco of the lung can be determined. (West, 2008a)
The diffusion properties of the alveolar membrane depend on its thickness and
area. The diffusion is also reduced when the surface area of the blood-gas barrier is
reduced. In obstructive diseases such as emphysema, the reduction in diffusing capacity
is partly due to destruction of alveoli and capillaries. The rate of combination of CO
with Hb is reduced when the number of red cells in the capillaries is low and also in
diseases that limit the capillary blood volume. (West, 2008a)
The diffusing capacity of the lung for the CO can be measured by three methods:
the single-breath method (which is the most commonly used), the Clarke Rebreathing
method and the Intra-breath method. The single breath method will be further discussed
44

in this paper, as it was the method used in this study to assess lung diffusion. In the
single-breath method, a subject takes a VC breath of CO and He, holds their breath for
10 s, and then exhales to RV. The first 750 ml are discarded because of dead space, and
the next litre is collected and analysed. Another gas, helium (He), is used as a tracer gas
and facilitates assessment of the dilution of the inspired gas (CO) to obtain the initial
alveolar CO pressure (Pco). According to West (2008), CO is absorbed from alveolar
gas proportionate to the Pco during a breath-hold; thus, the diffusing capacity can be
calculated as the volume of CO taken up per minute per mmHg alveolar Pco. (West,
2008a)
The advantages of this method include standardization by the ATS/ERS task
force (MacIntyre et al., 2005), good reproducibility and reference values available.
Disadvantages are the fact this measurement is performed at TLC, leading to difficult
patient co-operation and also a minimum of 1.3 litres VC is required. The rebreathing
method is a simple technique that requires a 1 litre anaesthetic bag to which the patient
is connected and the gas mixture is the same as that used for the single-breath method.
At the end of a normal tidal breath, a tap is turned and the subject breathes in and out
only from this bag, emptying it each time, at a rate of 10 breaths in 10 s. The
rebreathing time is recorded from a stopwatch and the contents of the rebreathing bag
are then analysed and the alveolar gas concentrations recorded. The major advantage of
this method is for patients who are unable to perform the breath-hold technique because
lung volumes are too small as no VC is required. However, this method also depends of
the patient co-operation and few reference values are available.
The third and last method to measure CO diffusion in the lung is called intrabreath and is a variation on the single-breath breath-holding method mentioned above.
There is no breath-hold and the subject inhales the test gas mixture of CO and CH4
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(Methane) from RV to TLC and then exhales gradually until RV is reached. The major
advantage of this technique is the lack of requirement for a minimum VC, although no
standardization for this measurement exists and only few reference values are available.
(Cooper et al. 2011)
Therefore, the single-breath breath-holding method is the most commonly used
to access the DLco of the human lung.

1.3.6 Historic Development of DLcoSB measurement

The use of CO to measure diffusion capacity was introduced by Christian Bohr in 1909
when he reported that the affinity of Hb for CO was greater than the affinity of Hb for
O2. He also reported that even if small concentrations of CO in alveolar gas were used,
the back pressure of the carboxyhaemoglobin (COHb) in the pulmonary capillary blood
could be ignored. (Cooper et al., 2011)
In 1915 August and Marie Krogh (Forster et al. 1954) introduced the idea that
the CO was transferred to the alveolar space by diffusion alone and they designed a
measuring method which included a period of breath-holding. Krogh asked subjects to
inhale a VC breath of CO as two alveolar samples were collected, and while the first
sample was collected during an immediate exhalation to about ½ VC, obtaining the CO
concentration at the beginning of the breath-hold, the second sample was collected after
six to ten seconds of breath-hold measuring the CO final concentration.
For the determination of the VA, the dilution of hydrogen method was applied,
where the end volumes of the two expirations represented the alveolar gas and were
analyzed for CO concentration. To Krogh the CO concentration fell exponentially and
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could be calculated by the following equation 1.7.

Eqt. 1.7 From Forster
et al., 1954.

In the above 1.7 equation the FA is the alveolar concentration of CO at time t,
representing the final sample; the FA0 is the alveolar concentration at time zero, the
initial sample; the “exp” is e; the base of the natural logarithms, raised to the power
contained in the brackets following: D ids the pulmonary diffusing capacity for CO; VA
is the total alveolar gas volume during the period of breath-holding; t is time in seconds
between the delivery of the two gas samples; and Pb is the total barometric pressure
minus 47mmHg. In this equation (Forster et al. 1954) the CO concentration on the first
sample was representative of all alveolar gas and that the CO tension in the pulmonary
capillary plasma (Pc) could be ignored. However, Roughton (1945) reported later that
Pc should be considered.
The Krogh equation describes diffusion of CO into the blood for time of breathholding during apnoea:

Eqt. 1.8 From Qutayba, A. Shannon, J. Martin, J. 2005.

Later Forster et al. (1954) suggested the addition of He to the Krogh method and
also the reduction to a single gas collection at the end of a known period of breathholding. (Forster et al., 1955)
In 1957, a similar paper was published by Olgivie et al. (1957) which
incorporated all the modifications mentioned by Forster and standardized the technique
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for the single-breath DLco method. Ogilvie proposed the elimination of the first
alveolar sample by adding He, an inert gas, to the mixture test gas and standardized the
DLcoSB measurement, still in use currently, where subjects rapidly inhale a test gas
mixture containing CO, He, O2 and N2 from RV to TLC. After a 10 second breath-hold,
subjects exhale again to RV. The major modification introduced by Ogilvie was the
parallel measuring of He dilution to estimate the concentration of CO at the onset of
breath-holding. In this technique all the alveolar gas was collected except the first litre
(used to washout the VD) and breath-hold time was measured from the start of
inhalation (t0) to the beginning of the sample collection (t1).
Jones and Meade (1961) realized that Krogh equation was valid only for the
breath-hold time portion during apnoea in the Ogilvie method (Ogilvie et al. 1957).
Errors in the CO diffusion measurement could be minimized by measuring the breathhold time from 3/10 of the time of inhalation to the time for one-half of the alveolar
sample collection, and also by collecting a smaller alveolar gas sample. (Qutayba, A.
Shannon, J. Martin, J. 2005)
Modifications of Ogilvie’s method to calculate DLcoSB are the current methods
in use and VA is measured from the single breath dilution of He as proposed by
McGrath and Thompson (1959) as shown by the equation 1.9.

Eqt. 1.9 From Qutayba, A. Shannon, J. Martin, J., 2005.
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1.3.7 Respiratory Gas Analysis

Analysis of respiratory function involves the measurement of gas concentrations
where precise measurements are crucial and the analyzer used should provide a rapid,
accurate, linear, stable and specific response to the gas being analysed. How fast an
analyzer detects a change in the gas concentration is an important factor. In order to
produce a feasible measurement of gas concentration at any instant in time, the response
of the analyzer should be preferably of 100ms or greater. (Cooper et al., 2011) Figure
1.11 illustrates the delay time and response time of a gas analyzer.
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Fig. 1.11
Definition of delay time and response time of a gas analyser,
From Cooper et al., 2011.
The delay time is defined as the amount of time it takes for a sample to reach the
analyzer, and is the time taken by the gas to travel from the sampling end to the
entrance of the analyser. The delay time is represented by the straight line portion
of the response time graph. During the delay time, the response time graph remains
flat, since no gas has yet reached the analyser. As soon as the test gas sample enters
the sample chamber, the gas begins to rise and this will mark the rise time of the
curve. The response time is the delay caused by transit time and rise time. In the
response time graph, rise time is the time required for the displayed value to rise
from the baseline to the maximum value.

To design and construct a gas analyser, the physical properties of gases are taken
into account and consequently a variety of gas analysers exist. In respiratory function
testing, the accuracy of the gas analyser of respiratory gases can be affected by the
presence of other gases in the sample, typical examples being water vapour and CO2.
Water vapour will dilute the gas to be analysed and should be removed from the sample.
CO2 is removed by granules containing barium hydroxide or sodium hydroxide, also
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called soda lime. (Cooper et al., 2011)
Analyzers used to measure CO gas diffusion in the lung are an Infra-Red or an
Electro-chemical type analyzer. In the Infra-Red analyzer, infra-red radiation is
absorbed by gases such as CO2 and CO in proportion to their concentration. A single
element coil with a filter will constitute the IR source, so that only the wavelength to the
gas being analysed is emitted. Since CO and the CO2 have close IR absorption bands,
the presence of one in the sample being analysed will interfere with the analysis of the
other. This interference can be minimized by the use of a filter tube manufactured to the
optical pathway. (Cooper et al., 2011)
CO can also be analysed using an electrochemical sensor as shown in figure
1.12, which consists of a sealed fuel cell with an aqueous electrolyte containing a
sensing and reference electrode with a constant voltage supplied by a battery. CO will
diffuse into the cell oxidising at the platinum anode according to the equation 1.10:

Eqt. 1.10 From Cooper et al., 2011.

Where e- is an electron and at the reference electrode the reaction is describe by
equation 1.11:

Eqt. 1.11 From Cooper et al., 2011.

The flux of e- resulting from this electrochemical reaction is recorded and is
directly proportional to the partial pressure of CO. In contrast to the IR analyzers, the
electrochemical ones are not affected by CO2 and only filters for water and alcohol
vapour are used. Each time the analyzer is used, a full scale calibration is performed
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with air and a CO/air mixture. (Cooper et al., 2011)

Fig. 1.12
Diagram of the fuel cell for electrochemical analysis of CO.
From Cooper et al., 2011
The fig. represents a sealed fuel cell with an aqueous electrolyte with
sulphuric acid containing a platinum sensing electrode and reference electrode with a constant
0.15 voltage supplied by a battery.

Another gas analysed during lung diffusion assessment is He which is measured
by a thermal conductivity analyzer. This type of analyzer measures the rate at which
heat is conducted by a gas, the thermal conductivity of a gas. The thermal conductivity
of He is much higher compared with other respiratory gases. This type of analyzer
consists of a Wheatstone bridge compromising four resistances with a constant given
bridge current, so that the temperature and the resistance remain constant. Of these four
resistors, one is the reference cell sealed with a gas of known concentration or exposed
to atmosphere and one the measuring cell. If the Helium concentration changes in the
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reference cell, the temperature and resistance in the measuring cell will change - more
heat is conducted and the resistance will fall, proportional to the He concentration
change. Thermal conductivity analyzers are stable, linear, calibrated at zero with air and
contain a CO2 and water vapour absorber through which the sample being analysed
passes. (Cooper et al., 2011) Calibration should be performed daily or before the
analyzers are used, the readings recorded in a logbook and the minimal requirement to
obtain a quality test is a two point calibration: a zero point and a full scale deflection.

1.3.8 Diffusing capacity for CO by the Single Breath Method

The single breath breath-holding measurement is based on the measurement of
CO uptake over a short period of time by the estimated difference of the partial pressure
between the alveoli and the pulmonary capillary blood.
Measurement of the diffusing capacity of the lung by the single breath method
requires a mixture containing the actual test gas, CO and an inert gas that allows
alveolar volume assessment, He. He is a stable gas that is almost inactive and relatively
insoluble and therefore is called the tracer gas due to its chemical properties. He is used
to determine the CO initial concentration, as well as the VA. Diffusion of the tracer gas
should be similar to the transfer gas (CO), not interfere with the measurement of CO
concentration and also be absent in alveolar gas. In this method the subject inspires a
vital capacity breath from a system with a spirometer containing a gas mixture of 0.3%
CO, 10% He, 21% O2, and the balance N2. First, the subject exhales completely to RV
and then inhales the gas mixture and holds breath at TLC for 10 s. Before the breathhold, a valve opens allowing exhalation to the spirometer and a sample of alveolar gas
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is collected in a bag, after the washout volume is discarded, as illustrated in figure 1.13.
The washout volume contains gas from the anatomical and instrumental dead space and
should be about 750 to 1000ml, unless the VC of the subject is less than 2000 ml in
which case the washout volume should be reduced to 500ml. The instrumental VD
represents the mouthpiece, filters and connections within the valve system, and should
be specified by the manufacturer. The anatomical VD is the volume of the conducting
airways that are not involved in gas exchange and the most commonly used formula for
its calculation is by the equation 1.12.

Eqt. 1.12 From MacIntyre et al., 2005.

Alveolar gas sample contamination with VD gas may interfere with measured
CO uptake. Therefore, its correct estimation is particularly important, as He
concentration in expired gas will indicate the effective dilution of the inspired gas with
the alveolar gas and give the initial alveolar CO pressure. (Ruppel, 1998)
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Fig 1.13
Trace obtained during the single breath breath-hold transfer factor measurement.
Trace shows the inspired volume breath-hold time, washout and sample volumes.
From Cooper et al., 2011

The DLcoSB method assumes that both CO and He are similarly diluted in
inspiration. The sample collected is analysed and the fractional CO and He
concentrations in the alveolar gas obtained. The equation 1.13 illustrates how the initial
concentration of CO is calculated:

Eqt. 1.13 From Cooper et al., 2011.
Where:


FICO is the fraction of CO in the reservoir (usually 0.003);



FIHe the fraction of He in the inspired gas (usually 0.10);



FACO0 is the initial CO concentration in the alveoli at the
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beginning of the breath-hold;


FAHe the fraction of He in alveolar gas.

The variation of the He concentration will predict dilution by gas remaining in
the lungs and allow the assessment of the FACO0 before any gas is diffused from the
alveoli into the pulmonary capillaries.
The DLcoSB is calculated by Krogh’s standard equation 1.14:

Eqt. 1.14 From Ruppel, 1998.

Where:


VA is alveolar volume, ml (STPD),



60 is correction from seconds to minutes,



PB is the barometric pressure, mmHg,



47 is the water vapour pressure (PH2O) at 37°C, mmHg,



T the breath-hold interval, seconds,



Ln the natural logarithm,



FACO0 the fraction of CO in alveolar gas at the beginning of the

breath-hold,


FACOT the fraction of CO in alveolar gas at the end of

breath-hold.
If abnormal distribution of inspired volume is present, such as in airway
obstruction, poor gas mixing can occur and this can reduce the transfer gas dilution and
thus lead to a lower measured VA value.
56

There are several methods of measuring the breath-hold time, which estimates
the time of contact between the test gas mixture and the red cells during gas exchange.
In order to standardize its measurement, the ATS/ERS guidelines (MacIntyre et al.,
2005) recommend the Jones and Meade method (Jones and Meade, 1961) of the three
available methods described in figure 1.14, in which “the breath-hold time equals the
time starting from 0.3 of the inspiratory time to the middle of the sample collection time
and the time when 90% of the inspired volume is achieved”. (MacIntyre et al., 2005)
The other two methods are the Olgivie method (Olgivie et al., 1957) that measures the
breath-hold time from the beginning of inspiration to the beginning of alveolar sample
collection and the Epidemiologic Standardization Project (ESP) that measures the
breath-hold time from the time of 50% of inspired volume (VI) is achieved to the
beginning of alveolar sample collection.
According to Ruppel, the DLco measured with the ESP method might be higher
if breath-hold time starts at the midpoint of VI. Similarly, some diffusion occurs during
washout and alveolar sampling if, as in the Jones and Meade method, the breath-hold
time period is extended into the alveolar sampling phase and the real time of breath-hold
is increased and the additional diffusion measured. (Ruppel, 1998)
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Fig. 1.14
Schematic illustration of different methods of measuring
breath-hold time for the DLcoSB. From MacIntyre et al., 2005
The method by OGILVIE(–) measures breath-hold time from the beginning of inspiration to the
beginning of alveolar sample collection. The method by JONES and MEADE(----) includes
70% of inspiratory time and half of sample time.
The Epidemiologic Standardization Project (– – – –) measures breath-hold time from
the time of 50% of VI to the beginning of alveolar sample collection. The time of inspiration (tI)
defined from the back-extrapolated time 0 to the time that 90% of the VI has been inhaled.

The breath-hold time should be measured by an accurate timing device able to
measure 100ms over a 10 second interval. Most modern computerized systems time the
breath-hold automatically. (Ruppel, 1998)
In order to standardize the DLCO measurement some precautions should be
taken. According to the ATS/ERS task force guidelines (MacIntyre et al., 2005), the
interval between tests should be at least 4 minutes and in patients with obstructive lung
disease up to 10 minutes, which will allow an adequate washout of test gas from the
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lungs. Also, the patient should remain seated during this time.
MacIntyre et al. (2005) emphasises that some considerations must be taken
before measuring DLcoSB such as diurnal variation in DLco, ingestion of ethanol
(reported to decrease DLco) and administration of bronchodilators before the test (may
increase DLco by up to 6%). Also supplemental oxygen should not be administered at
least 10 minutes before test. Subjects should refrain from smoking 24 hours before the
test (time of the last cigarette smoked should be noted), as smoking is a major source of
carboxyhaemoglobin and may lead to a reduction in measured DLco reduction, due to
effects on CO back pressure that decrease the Hb available to combine with CO from
the test gas. (MacIntyre et al., 2005) At least two acceptable tests should be recorded
and meet the repeatability criteria of “either being within 3 ml CO (STPD) · min-1 ·
mmHg-1 of each other or within 10% of the highest value” in order to obtain an accurate
DLco measurement. The acceptability test criteria for DLCOSB measurement, according
the ATS/ERS guidelines, are the use of quality-controlled equipment, an inspired
volume of at least 85% of the higher VC in less than 4 s, no evidence of leaks, a stable
breath-hold for 10 s, an expiration of less than 4 s with sample collected in less than 3 s
and sufficient VD clearance.
Whether Hb should be standardised, in normal subjects or patients, for DLcoSB
measurement is still being debated, as the cost of measuring Hb in every patient during
routine clinical assessment is high in relation to the small improvement in accuracy of
the measurement. According to Cooper et al. (2011) unless the Hb concentration is <
11.0 g.dl-1 or > 18 g.dl-1, correcting the Hb for each DLcoSB measurement will add a ±
5% difference. For that reason, Hb correction should be applied in conditions where the
Hb concentration is expected to be low or changing. The standard Hb value is assumed
to be 14.6g.dl-1 in adult males and adolescents and 13.4g.dl-1 in adult females and
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children < 15 years old, but equations 1.15 for adult males and 1.16 for adult females
and children <15 years old can be used for adjusting the DLco predicted:

Eqt. 1.15 From MacIntyre et al., 2005

Eqt. 1.16 From MacIntyre et al., 2005

CO diffusion depends mainly on two conductance properties which are the rate
of combination of CO with Hb, expressed as the product of the CO-Hb reaction rate (θ)
and the volume of Hb in alveolar capillary blood (Vc); and the membrane conductivity
(DM) which predict the diffusion properties of the alveolar capillary membrane. Several
physiological and pathological processes can affect DM, θ and Vc and interfere with the
DLCO. (MacIntyre et al., 2005) Conditions such as respiratory muscle weakness and
thoracic deformity that can lead to a reduction in lung inflation (which consequently
reduces VA) will decrease effort and produces changes in DM, θ or Vc reducing DLCO.
Also, diseases like anaemia and pulmonary emboli, as well as Hb binding changes and
the Valsalva manoeuvre can reduce θ and Vc and thus reduce DLCO. Lung resection,
emphysema, interstitial lung disease, pulmonary oedema, pulmonary vasculitis and
pulmonary hypertension reduce DM, θ and Vc and thus reduce DLCO. Other conditions
and diseases can increase θ and Vc and increase DLCO, as such polycythaemia, left-toright shunt, pulmonary haemorrhage, asthma, Hb binding changes, the Muller
manoeuvre, exercise, the supine position and obesity (possible DM component).
(MacIntyre et al., 2005)
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Diseases that are associated with abnormally increased alveolar-capillary
membrane thickness, such as interstitial lung disease, lead to a reduction in the diffusing
capacity of the lung and it is also reduced when the surface area of the blood-gas barrier
is reduced, such as after a pneumonectomy. In emphysema, low diffusing capacity of
the lung is caused by the destruction of alveolar walls and capillaries (West, 2008b).
Thus, DLco measurement is a useful tool for the clinical assessment, diagnosis and
management of both obstructive and restrictive pulmonary disorders (Ruppel, 1998).
The degree of severity of decrease in diffusing capacity for carbon monoxide is
defined by the ATS/ERS guidelines (Brusasco et al., 2005) as mild where DLcoSB and
KCO% predicted are between the lower limits of normal and above 60%, moderate
where DLcoSB and KCO % predicted are between 40 and 60% and severe where DLco
and KCO% predicted are below 40%.
The DLcoSB reflects the uptake of CO per unit pressure difference between the
alveoli and pulmonary capillary and if the CO diffusion within the lung is normal,
abnormalities of DLco suggest disease at alveolar level. The KCO, also called transfer
factor, attempts to correct alterations in the VA of the subject, due to an inadequate
inspiration to TLC during DLco measurement in normal lungs or with maximal
inspiration in the presence of respiratory disorders that reduce the VA. The measured
DLco is divided by the VA during CO diffusion measurement. According to Brusasco et
al. (2005) when “the KCO is multiplied by the volume of gas in the lung containing CO
(alveolar volume), the total uptake of CO by the lung per unit of time per unit driving
pressure is obtained, this product being termed the transfer factor of the lung (KCO)”.
Interpreting DLco and KCO requires an understanding of normal physiology and
of pathophysiological effects of the disease being assessed. The predicted reference
values for VA, DLco and KCO should be used from the same source and factors that
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interfere with DLco and KCO measurement should be considered when interpreting the
results. The most commonly used predicted reference values equations for DLcoSB
calculations are those from 1993 ERS document. (Jones and Meade, 1961)

1.4 Abnormalities of Gas Exchange in Human Lung

1.4.1 Chronic Obstructive Pulmonary Disease

According to the ATS/ERS task force (Celli et al., 2004), chronic obstructive
pulmonary disease (COPD) is a “preventable and treatable disease state characterised by
airflow limitation that is not fully reversible. The airflow limitation is usually
progressive and is associated with an abnormal inflammatory response of the lungs to
noxious particles of gases, primarily caused by cigarette smoking”. COPD commonly
produces pathological changes in four different compartments of the lungs: the central
airways, peripheral airways, lung parenchyma and pulmonary vasculature, and despite
being primarily a disease of the lungs, can also lead to significant systemic effects.
(Celli et al., 2004)
COPD is an umbrella term for a combination of emphysema and chronic
bronchitis (peripheral airway obstruction). Emphysema is characterized pathologically
by alveolar wall destruction which leads to enlargement of airspaces and loss of lung
elasticity, obstruction of peripheral airways and destruction of the capillary bed. Chronic
bronchitis is characterized by peripheral airways obstruction due to inflammation and
excessive mucus production by hypertrophy of mucous glands. The abnormal amount of
mucus in the airways may obstruct some of the small bronchi. (West, 2008b) Airway
obstruction in patients with COPD will increase resistance to the airflow. Loss of radial
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traction from destruction of the lung parenchyma will also cause airway narrowing,
particularly in the peribronchial region of the airways.
The increase in airflow resistance in COPD will amplify the effect of the static
recoil pressures reduction on the normal pressure gradient between the alveoli and the
mouth. The loss of elastic recoil and excessive contraction of abdominal muscles will
decrease intraluminal pressures during expiration, leading to airway collapse. This can
be summarized in fig. 1.15 where an equal pressure point model is used.
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Fig. 1.15
Model illustrating pleural pressures,
accessed 4 April 2012, http://flylib.com/books
Equal pressure point model where static recoil pressure is +10 cm H 2 O.
In scenario A (static conditions) no flow is present and the forces of elastic recoil and chest wall
recoil are balanced. As forced expiration occurs in presence of airway obstruction in scenario B
(Dynamic conditions), the thoracic pressure becomes positive, frictional pressure losses within
the airway occur reducing the intraluminal pressure. When the critical point is reached, airway
collapse may occur and despite further increases in intrathoracic pressure, expiratory flow will
remain constant.

In this diagram a critical pressure point occurs in the airway where the
expiratory flow is independent of any extra applied pressure, explaining the typical
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expiratory flattening of the flow-volume loop in COPD obtained by spirometry (Fig.
1.16). This explains why the FEV1 and the FEV1/FVC ratio assessment are of great
importance in COPD patients.
Figure 1.16 demonstrates why patients with severe COPD achieve maximum
expiratory flow during tidal breathing, reducing their capacity to increase ventilation
without increasing either lung volumes or inspiratory work.

Fig. 1.16
COPD flow volume loop,
accessed 4 April 2012, http://www.spirometrie.info/fvc.html
The air in the large airways can be expired without problems, so the PEF is will be normal.
When all the air is expired from the large airways, the air from the smaller airways will be
expired partially blocked and will come out slower and in a lower flow creating a sharp fall in
the flow-volume.
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The inflammatory response in COPD is caused predominantly by cigarette
smoking. An important feature of COPD pathogenesis is the imbalance of proteinases
and antiproteinases in the lungs, and oxidative stress. (Celli et al., 2004)
Hyperinflation is another important feature of COPD and that leads to a
significant elastic load to breathing, which becomes important as flow resistance
increases. Shortening of the diaphragm length can occur, changing the muscles fibre
orientation and leading to impairment of contraction. Also geometric changes will make
the development of tension harder to achieve. All these respiratory muscles changes will
increase the total work of breathing and oxygen consumption by respiratory muscles.
The loss of vertically oriented diaphragm muscles fibres, the increased work of the
pectoral muscles as accessory respiratory muscles, and the use of abdominal muscles
during expiration contribute to increased work of breathing in COPD. (Gross, N. 1993)
Farkas et al. (1983) reported that the respiratory muscles may adapt to the chronic
hyperinflation by a compensatory reduction in sarcomere numbers.
The diagnosis of COPD should be considered when symptoms of cough, sputum
production, dyspnoea or a history of exposure to risk factors for the disease are present.
Diagnosis requires confirmation of airflow obstruction by spirometry. If spirometry
after bronchodilator shows an FEV1/FVC ratio ≤ 0.7, the presence of airflow limitation
is confirmed, which in COPD case is not fully reversible. The Global Initiative for
Chronic Obstructive Lung Disease guidelines (Lenfant, C. Khaltaev, N. et al., 2003)
define COPD severity by a post-bronchodilator FEV1/FVC ≤ 0.7 and mild COPD
represented by FEV1 ≥ 80% predicted, moderate COPD by FEV1 50-80% predicted,
severe COPD by FEV1 30-50% predicted and very severe COPD by FEV1 < 30%
predicted. (Celli et al., 2004)
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Three types of bronchodilator are commonly used for management of COPD: β2agonists, anticholinergic drugs and methylxanthines. Despite differences in their site of
action in the airways, the most important effect of bronchodilator therapy is airway
smooth muscle relaxation and lung emptying during tidal breathing. Figure 1.17
illustrates the different types of bronchodilators and their site of action.

Fig. 1.17
Mechanisms of action of bronchodilators on airway smooth muscle,
accessed 4 April 2012, http://www.medscape.com
The anticholinergics act by blocking the effect of acetylcholine on muscarinic receptors (M1,
M2 and M3). Anticholinergics disassociates slowly from the muscarinic receptors, providing
bronchodilation. Beta-2 agonist drugs bind to beta-2 receptors on airway smooth muscle and
lead to an increase in the concentration of cAMP (cyclic adenosine monophosphate) in the
muscle cell which results in smooth muscle relaxation. When airway smooth muscle relaxes, the
diameter of the air passages is increased. Theophylline blocks the action of phosphodiesterases
and prevents the breakdown of cAMP to AMP (adenoside monophosphate). This also has the
effect of relaxing smooth muscle and allowing the airways to dilate.
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The FEV1 change in COPD after a bronchodilator is typically small but can
produce larger changes in lung volumes, thus reducing RV and hyperinflation. (Celli et
al., 2004)
The DLcoSB is often reduced in COPD, as emphysema reduces the lungs
surface area by loss of both alveolar walls and their associated capillary beds. The main
consequence is less gas transfer per minute even if the remaining gas exchange units are
structurally normal. The path length from the terminal bronchiole to the alveolarcapillary membrane in emphysema can be increased and gases must cross farther to
reach the alveolar-capillary surface. Airways collapse and gas trapping also produces
ventilation-perfusion abnormalities. (Ruppel, 2008)
Ventilation-perfusion inequality in COPD is caused by the disorganization of the
lung architecture in emphysema causing hypoxemia with or without CO2 retention.
Respiratory failure in COPD can occur in 2 settings: moderate hypoxemia with normal
arterial pCO2 (Type 1 respiratory failure), or severe hypoxemia with an increased pCO2,
typically seen in more advanced disease (Type 2 respiratory failure). A high alveolar–
arterial pO2 difference is always present (especially in severe bronchitis). VD is also
increased in emphysema. Destruction of the capillary bed causes uneven ventilation as
well as regional inequality of blood flow. However, impaired gas exchange and V/Q
inequality can be minimised by collateral ventilation (physiologic communicating
channels that exist between adjacent alveoli and between small airways) and hypoxic
vasoconstriction, a local response to low alveolar pO2 that reduces blood flow to poorly
ventilated areas. (West, 2008)
Despite V/Q inequality, arterial pCO2 can be normal in mild to moderate COPD,
but as severity progresses, the arterial pCO2 may increase. An important factor is the
increased work of breathing but also reduced sensitivity of the respiratory centre to
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CO2. The rise of pulmonary artery pressure in COPD as severity progresses contributes
to V/Q inequality as portions of the capillary bed are destroyed, increasing vascular
resistance and hypoxic vasoconstriction. (West, 2008b)
Physiologically significant changes in pulmonary circulation occur with disease
progression in COPD. The normal pulmonary circulation has great capacitance with low
vascular resistance, due to its ability to recruit additional capillary beds. Gross et
al.(1993) reported that in patients with COPD at rest, the mean pulmonary artery
pressure increases by “the loss of capillary bed due to emphysema, changes in blood
viscosity due to polycythaemia, altered alveolar oxygen tension due to a V/Q inequality,
or raised intrathoracic pressures”. Polycythaemia occurs due to daytime and/or
nocturnal hypoxia which can worsen with continued cigarette smoking (Calverley et al.,
1982). In advanced COPD, severe pulmonary hypertension can occur, reducing the
cardiac output.

1.4.2 Sarcoidosis

Sarcoidosis is defined by Fishman (2007) as a “multisystem disorder of
unknown origin aetiology characterized by noncaseating granulomatous inflammation
at sites of disease that frequently presents with bilateral hilar lymphadenopathy, ocular
and skin lesions”. Although any organ can be involved, this disorder predominantly
involves the lungs and lymph nodes. The diagnosis of sarcoidosis is frequently
established from clinical and radiologic findings, in combination with demonstration of
noncaseating epithelioid granulomas in affected organs and exclusion of other causes of
granulomatous disease. (Fishman, 2007)
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Although the cause of sarcoidosis is still uncertain, it is thought that genetically
susceptible hosts develop sarcoidosis when exposed to specific environmental agents.
This concept, as reported by Hunninghake et al. (1999), is supported the fact that the
inflammatory response present in sarcoidosis is characterized by activated macrophages
and CD4 helper T lymphocytes that lead to a profile of cytokine production that is
consistent with a Th1-type immune response triggered by an antigen. Fishman (2007)
states that clinical, epidemiologic, and family studies strongly suggest that exposure to
microbial agents when a genetic susceptibility is present can trigger sarcoidosis.
Sarcoidosis occurs between 20 and 40 years in 80% of cases, but also is seen in
women > 50 years. (Fishman, 2007) The course and prognosis of sarcoidosis may relate
to the pattern of onset of the disease. Sarcoidosis that presents acutely with erythema
nodosum and bihilar lymphadenopathy commonly shows a self-limiting course, and by
contrast, a more insidious onset is more likely to lead to progressive fibrosis of the
lungs. (Hunninghake et al. 1999)
The characteristic pathologic feature in sarcoidosis is the presence of
noncaseating epithelioid cell granulomas composed of differentiated mononuclear
phagocytes and lymphocytes. Commonly, sarcoidosis granulomas are located in lymph
nodes (especially intra-thoracic), lungs, liver, spleen and skin. These granulomas can
resolve spontaneously, or produce fibrotic damage, which can lead to parenchymal
fibrosis of the lung. (Hunninghake et al. 1999)
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Fig. 1.18
Pathogenesis of Sarcoidosis,
accessed 4 April 2012, http://highered.mcgraw-hill.com
The normal alveoli represented in the top and the alveoli in active sarcoidosis in the bottom.

The latter are distorted by the accumulated CD4&plus; TH1 lymphocytes, alveolar
macrophages, and macrophages aggregated into granulomas. There is mild damage to
alveolar epithelial and endothelial cells.
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Figure 1.18 shows how alveoli in active sarcoidosis may be damaged by
accumulated CD4+ Th1 lymphocytes, alveolar macrophages, and macrophages
aggregated into granulomas. The trigger origin for the Th1 lymphocytes is uncertain but
according to Hunninghake et al. (1999), a limited class of antigens or self-antigens
presented in the context of class II HLA surface molecules by mononuclear phagocytes
to the Th1 lymphocyte may be causal. Increased production of inflammatory mediators
such as TNF-alpha, IFN-gamma, and IL-12 is present. The antigen class II HLA
complex is identified by the T cell antigen receptor, and the T cell is activated. As a
result, Th1 lymphocytes will release IL-2, which causes activation of more T
lymphocytes. Macrophage inflammatory proteins and granulocyte-macrophage colonystimulating factor contribute to granuloma formation. The diagnosis of pulmonary
sarcoidosis is based on finding stable formed granulomas surrounded by lymphocytes
and fibroblasts in a perilymphatic interstitial distribution with no alternative cause.
In sarcoidosis the lungs are commonly affected, and in 30-50% of cases,
dyspnoea, dry cough and chest pain may occur. Pulmonary sarcoidosis is frequently
staged by radiographic findings, as reported by Hunninghake et al. (1999) Five chest
radiographic stages can be defined: stage zero, with no visible intrathoracic findings;
stage one where bilateral hilar lymphadenopathy is present, together in some cases with
paratracheal adenopathy; stage two with hilar adenopathy and parenchymal infiltration;
stage three with parenchymal infiltration without hilar adenopathy; and the last, stage 4
with advanced fibrosis and “honey-combing”, hilar retraction, bullae, cysts and
emphysema. Grutters et al. (2009) stages sarcoidosis based on data from patient studies,
interpreted in the context of experimental models of immune responses and in this
model, three stages are mentioned:
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Stage one, involves the exposure to present unknown exogenous or endogenous
antigenic proteins taken by the antigen cells and processed into peptide
fragments. These peptides are loaded by an histocompatibility Class II
molecules and taken to the T-Cell receptors of the T-lymphocytes ( Th0). The Th0
is activated and polarised as T-helper type 1 cells (Th1) under the influence of a
interleukin (IL).



Stage two, is characterised by a granuloma formation due to an ongoing
presentation of antigen by the lung macrophages to the Th1 cells. These will start
a well organized production of chemokines and cytokines by the Th1 cells which
leads to a high demand, migration and retention of cells such as T-lymphocytes
and macrophages. All these cells organize into immune granulomas, usually
non-necrotising.



Stage three, will involve the evolution of the granulomatous inflammation that
can resolve spontaneously or persist leading to a chronic course of disease and
the onset of a fibrotic response. This fibrotic process may lead to end-stage
sarcoidosis marked by parenchymal fibrosis and honeycombing pattern.

Commonly, pulmonary function is normal in stages zero and one of the disease,
but in stages two and higher, a non-obstructive ventilatory defect can be found. In this
setting, lung volumes will be decreased except for the FEV1/FVC ratio which is normal
as classified by the British Thoracic Society (Bellamy, 2005) and presented in table 1.1.
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Spirometry Parameters

Non Obstructive Disorders

FEV1

< 80% predicted normal

FVC

< 80% predicted normal

FEV1/FVC ratio

Normal (> 0.7)

Table 1.1 Spirometry Classification for non obstructive disorders

The Figure 1.19 illustrates a typical non-obstructive flow volume loop.

Fig. 1.19
Non-obstructive Flow Volume loop,
accessed 4 April 2012, http://courses.washington.edu
The shape of the flow volume loop is relatively unaffected in restrictive disease, but the overall
size of the curve will appear smaller when compared to normal on the same scale.
Similarly, there will be a rapid upslope on the volume time curve, but such patients will reach a
smaller vital capacity.
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Furthermore, in stages two or three the DLcoSB and KCO can be impaired. The
pO2 at rest may be low and can decrease significantly with exercise. The pCO2 can be
normal or low, but will rise in advanced stages. (West, 2008b)

1.4.3 Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF) is the most common cause of interstitial
lung disease and its cause is uncertain. IPF is characterised by a specific combination of
clinical, radiographic and pathological findings that lead to a progressive dyspnoea,
hypoxemia and ultimately death. The IPF incidence increases with age; two-thirds of
cases occur over the 60 years with a mean of 66 years at diagnosis. (Fishman, 2007)
Usually, IPF presents with gradual onset of cough and dyspnoea. Dyspnoea is
progressive and commonly reported for more than 6 months before diagnosis. IPF is
defined by Ruppel (1998) as a “specific form of chronic fibrosing interstitial pneumonia
limited to the lung and associated with the histologic appearance of usual interstitial
pneumonia on surgical lung biopsy”. The main feature is fibrosis of the interstitium,
leading to subpleural changes that are seen on chest x-ray and high-resolution CT
thorax, and at an advanced stage will show a “honey-combing” pattern.
In the early stages of IPF, infiltration with lymphocytes and plasma cells is
present and as the disease progresses, fibroblasts appear and form a thick collagen mass.
Further, the normal alveolar structure is destroyed and the typical scarring (illustrated in
the figure 1.20) leads to empty cystic spaces in the terminal and respiratory bronchioles.
(West, 2008b)
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Fig. 1.20
Alveoli with Pulmonary Fibrosis,
accessed 4 April 2012, http://www.mountnittany.org
Pulmonary fibrosis is scarring of the lung tissue between the alveoli and the blood vessels. If
scarring is severe, O2 can not easily move from the air in the alveoli to the blood in the vessels.
As a result, the blood does not deliver enough O2 to the body.

Interstitial lung disease may arise from the use of medications such as bleomycin
or amiodarone and can co-exist with autoimmune diseases such as rheumatoid arthritis,
systemic lupus erythematosus and scleroderma, as these disorders can result in alveolar
wall inflammation and fibrotic changes. (Ruppel, 1998) Therefore, other causes of
interstitial lung disease should be excluded before the diagnosis of IPF is confirmed.
Pulmonary function and lung imaging studies can be normal in early IPF. (King
et al., 2000) However, as IPF advances, pulmonary function testing will show a nonobstructive ventilatory defect with reduced FVC and FEV1 and normal FEV1/FVC ratio
with reduced lung volumes (VC and TLC). Gas exchange is typically affected as the
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alveolar-arterial pressure difference for O2 is increased. The reduction in DLCO may
precede lung volume impairment. (Cooper et al., 2011)
The blood volume of the pulmonary capillaries decreases in IPF due to vessels
destruction by the fibrotic process. The hypoxemia that results from reduced DLco is
usually mild at rest and will increase as IPF advances, where physiological VD and
shunt are increased. Decreased pCO2 occurs due to increased ventilation to the alveoli.
The work of breathing will also be increased in IPF as hyperventilation due to high
respiratory rates is present. The most important cause of hypoxemia in IPF is V/Q
mismatching, not anatomic shunting or reduced O2 diffusion. (Fishman, 2007)
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Chapter 2

METHODOLOGY

2.1 Study Protocol

The study involved the measurement of spirometry and CO diffusion capacity by
the single-breath method in healthy subjects, patients with severe COPD and patients
with interstitial lung disease (IPF and sarcoidosis patients with interstitial fibrosis)
recruited from the Mercy University Hospital outpatient clinic. CO diffusion was
measured with a standard 10 s breath-hold time and then repeated with an 8 s and 6 s
breath-hold to determine if breath-hold time reduction led to significant differences in
measured DLco. The Clinical Research Ethics Committee of the Cork Teaching
Hospitals approved the protocol. After detailed explanation of the reasons for the study,
informed consent was obtained from the subjects for participation in the study .

2.2 Study Criteria

The inclusion and exclusion criteria were identified based on the the ATS\ERS
guidelines for the DlcoSB measurement (MacIntyre et al., 2005). The ATS/ERS
taskforce reports that some physiological and pathological changes can affect DLco
measurements. Therefore, all subjects with asthma, obesity (BMI > 30), history of lung
resection, anaemia (Hb<11 g/dL), recent pulmonary embolus (< 6 months), recent
pulmonary haemorrhage (< 6 months), polycythemia, pulmonay oedema, pulmonary
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vasculitis, left-to-right shunt, respiratory muscle weakness or thoracic deformity, severe
cognitive dysfunction or psychiatric ilness and unstable comorbidity (uncompensated
congestive heart failure, severe pulmonary hypertension, unstable angina or recent
myocardial infarction) were excluded from the study. (MacIntyre et al., 2005)
The ATS/ERS guidelines also state that the use of supplemental O2 10 minutes
before the DLco measurement and exercise 1 hour prior to testing testing can affect the
pulmonary capillary blood volume and therefore the DLco value. Patients were
instructed not to use supplemental O2 10 minutes and also not to perform exercise
before measurements. The consumption of alcohol within 24 hours of testing has been
reported to decrease DlcoSB measurements (MacIntyre et al., 2005; Wanger et al. 2005)
as some fuel-cell CO analysers are sensitive to exhaled ethanol and ketones. Therefore
patients were excluded if alcohol consumption was not avoided.
Active smokers were excluded as COHb can decrease measured DLcoSB due to
CO back presssure effects and the reported “anaemia effect” decreasing Hb binding
sites for CO. (Viegi et al., 1998), and consequently all study subjects were non-smokers
or ex-smokers for more than one year.

2.3 Study Group

The study group consisted of 90 subjects who met the inclusion criteria. There
were 30 healthy controls, 30 patients with COPD and 30 with interstitial lung disease
(sarcoidosis with pulmonary fibrosis or IPF) all recruited from the Mercy University
Hospital Outpatient clinic by a respiratory consultant. All subjects performed baseline
Spirometry and DLcoSB in the respiratory laboratory of the Mercy University hospital
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before recruitment, part of the routinely clinical respiratory assessment conducted by the
respiratory team.
The healthy controls had no history of airway or lung disease and had normal
pulmonary function (FEV1/FVC > 70%, DLco > 80% predicted and KCO > 80%
predicted).
The COPD group had a pre-existing diagnosis of COPD and were included if
FEV1/FVC was < 70% and FEV1 was 30-50% predicted, after inhaled bronchodilator.
The ILD group had a pre-existing diagnosis of sarcoidosis stage two with pulmonary
fibrosis or IPF and were included if FVC < 80% predicted, FEV1/FVC ratio >70% and
DLcoSB < 80% predicted. (Miller et al., 2005)

2.4 Measurements Protocol

All measurements were performed in the Respiratory Laboratory of the Mercy
University Hospital by the same certified Senior Respiratory Scientist with the subject
seated and at rest. All measurements were performed between 9am and 1pm, as diurnal
variation caused by a combination of changes in CO back pressure and diurnal variation
in Hb concentration can affect the DLco measurements. (Cinkotai and Thomson, 1966;
Frey et al., 1987)
All subjects performed at first spirometry according to the ATS/ERS
recommendations (Miller et al., 2005) allowing the FEV1, FVC and FEV1/FVC ratio
assessment. Spirometry was recorded by a Jaeger Master-Screen PFT (Appendix B).
After spirometry measurement the Hb was measured in all study subjects with
an Hemocue Hb 201+ (Appendix A), necessary for the Hb value adjustment in all
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following DLcoSB measurements, according to the ATS/ERS recommendations.
(MacIntyre et al., 2005)
The first DLcoSB measurement with a 10 s breath-hold time was performed in
all subjects according to the ATS/ERS guidelines (MacIntyre et al., 2005), to ensure that
every subject met the minimum cooperation requirements for the study.
Before each DLcoSB measurement the analyser was zeroed against room air.
Each subject was studied in the sitting position, at rest and with a nose clip in place.
After a stable VT, each subject exhaled to RV and then inhaled a gas mixture containing
0.28% CO, 9% He, 19% O2 and the remainder N2 to TLC. The software took into
account the time delay between volume and gas fraction signals. When TLC was
reached, a digital clock began timing the breath-hold, and after 10 s of breath-hold, the
patient exhaled again to RV and a sample was collected for analysis. The breath-hold
time was measured according to the Meade-Jones method (Jones and Meade, 1961)
which assumed that the breath- hold time equals the time starting from 30% of the
inspiration time to the middle of the sample collection time. The inspiratory time was
defined when 90% of the VI was reached determining the end point.
The DLco in this study was measured by the single breath method of Ogilvie et
al. (1957) as modified by Jones and Meade (1961). The initial 750 ml of exhaled breath
was discarded (representing the VD) and the next 750 ml of gas sample was used for
analysis (or 500 ml if the subject’s VC was < 2L) (MacIntyre et al., 2005) The CO
fraction was determined by an electrochemical analyser and the He by a thermal
conductivity analyser.
Two acceptable tests for each measurement were recorded, meeting the
repeatability requirements of ATS/ERS recommendations (MacIntyre et al., 2005) of
either being within 3 mL CO (STPD).min-1.mmHg-1 of each other or within 10% of the
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highest value. At least 4 minutes were allowed between tests to provide adequate
elimination of test gas from the lungs and in the COPD group a 10 minutes interval was
given according to the same guidelines. (MacIntyre et al., 2005). All subjects remained
seated during this period.
DLcoSB was calculated according to the standard equation:

Eqt. 2.1 From MacIntyre et al., 2005.

In equation 2.1 the VA is in ml STPD, t is the time of breath-hold and PH2O is the
water vapour. The VA was measured from the He dilution as shown in the equation 2.2:

Eqt. 2.2 From MacIntyre et al., 2005.

If the subject met the recruitment inclusion criteria for the study, an informed
consent was obtained by a respiratory consultant at the out-patients clinic of the Mercy
University Hospital for participation in the study.
After 1 hour of rest following the first DlcoSB measurement with 10 s breathhold, another measurement with breath-hold time reduced to 8 s was repeated followed
again by 1 hour of rest until the last measurement with 6 s of breath-hold. All subjects
remained in the waiting area of the Respiratory Laboratory of the Mercy University
Hospital between the measurements.
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In the COPD group all measurements were performed after inhaled
bronchodilator therapy, which was not suspended for the study. It has been reported that
the bronchodilator administration may increase the DlcoSB measurements up to 6%
while affecting the VA and vasomotor tone. (MacIntyre et al., 2005) The bronchodilator
effect was taken into consideration when the results were analysed.
All measurements were part of the clinical respiratory assessment routinely
conducted by the respiratory team. The only additional to the routine procedure was the
breath-hold time reduction in the DLcoSB, which required two additional measurements
to achieve the aim of this study.
The figure 2.1 summarizes the present study design.
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Fig. 2.1 Study Design
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2.5 Measurement Equipment

Two types of equipment were used during the study, both in the Pulmonary
Function Laboratory of the Mercy University Hospital. A brief description of each
device, the basic principle of operation and its primary function in the study are given in
this chapter.

2.5.1 Jaeger Master Screen PFT

This is a complete system for recording spirometry, pulmonary diffusion
capacity and lung volumes.
This system allows spirometry and CO-Diffusion by the single breath method
measurement. Spirometry was performed in all subjects to assess FEV1, FVC and
FEV1/FVC, followed by DLcoSB, KCO,VD, VA, FAHe and FAco assessment at three
different breath-hold times of 10, 8 and 6 s with a gas mixture of 0.28% CO, 9% He,
19% O2 and the remainder N2. (Appendix A).
The volume and gas analysers used were calibrated daily according to the Irish
Association Respiratory Scientists Quality Assurance guidelines (IARS, 2011). The
Flow Measuring Sensor Calibration establishes the relationship between sensordetermined values of flow or volume and the real flow or volume is named calibration.
(Brusasco et al., 2005)
Calibration was performed twice daily with volume checked by a 3L syringe,
which was within 3% or 50 ml/s. This 3L syringe should read between 2.91 and 3.09 L
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in calibration mode. Also linearity checks of flow rates between 2-12 L/s were
performed weekly by adjusting the speed of the syringe in the flow sensing devices to
cover the range of flows produced by the patient population, as low (2L/s), medium
(6L/s) and fast flows (12L/s). The calibration syringe used was periodically leak tested
at more than one volume up to it maximum and had a valid calibration certification.
A second calibration was performed to the gas analyser. This calibration is called
two-point calibration, where two gas concentrations are used. One gas concentration
was used to zero the low end of the range and the second one was used to adjust the
high end of the range. The main goal of this calibration is to adjust the analyser value in
order to match the input of the known concentration of a gas. (IARS, 2011) This
calibration was performed twice daily and was within ±1% of initial gas concentration.
Stability is of major importance in analyzers, with minimum drift (< ± 0.5% of full
scale) between calibration and testing, therefore the reading of the analysers was
checked to detect any drift during testing. Quarterly gas analysers timing should be
consistent with gas flow rate at a constant 200ml/min with a response time of less than
30 s, which was checked during annual service.
Prior to and after each measurement the gas analysers were zeroed and the gas
calibration was performed at the time of the volume calibration.

2.5.2 Hemocue Hb 201+

This is a portable system used for the determination of the total amount of
haemoglobin in whole blood (Appendix B). The system consists of a specially designed
analyzer with microcuvettes containing dried reagents. The haemoglobin measurement
takes place in the analyzer, which follows the progress of the reaction until the end point
86

has been reached. This equipment allowed the quantitative determination of
haemoglobin on every patient before the CO-diffusion measurement.
No calibration process was necessary before each measurement. The system is
factory calibrated against the haemiglobincyanide method, the international reference
method for the determination of the haemoglobin concentration in the blood (Davis and
Jungerius, 2010), and needed no further calibration. The analyzer has an internal quality
control process that automatically verified the performance of the optronic unit during
each measurement.

2.6 Data storage and patient confidentiality

All data pertaining to the study was stored in a computerized database on an
encrypted departmental computer and backed up on CD and USB drives kept in a
locked press in a locked office in the Respiratory Laboratory of the Mercy University
Hospital. Data was available only to the principal investigator and co-investigators.
Informed consent forms and other paper records pertinent to the study were kept
by the principal investigator in a locked office. Personal data was stored, processed and
analyzed in an anonymized format. This format did not include name, date of birth,
address or medical record number of the subjects.
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Chapter 3

DATA ANALYSIS AND RESULTS

3.1 Introduction

This chapter presents the analysis and results of the data from this study. The
study limitations regarding data collection and the statistical methods employed in the
analysis are described first, followed by the details of the group characteristics and the
data analysis.

3.2 Study Limitations

The main limitation of this study laid on the subject recruitment, as different
groups were difficult to match for age and gender. This limitation justified the
recruitment of 5 ex-smokers for the control group that, despite of being ex-smokers, met
the inclusion and inclusion criteria for the control group, with normal spirometry
(FEV1/FVC>70%, FEV1>80% pred and FVC>80%), normal DLcoSB (DLcoSB>80%
predicted and KCO>80% predicted) and no history of respiratory impairment or lung
disease.
Despite of the required maintenance of 10 s breath-hold and inspiration to TLC
for the single breath method in the DLcoSB measurement, all subjects were able to
perform all measurements in the study and meet the inclusion criteria.
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3.3 Statistical Methods

In total, 36 variables were analysed. Kolmogorov-Smirnov testing was used to
determine whether data were normally distributed. Comparisons between groups were
made using two-tailed parametric testing or nonparametric testing, depending on
whether data were normally distributed. Comparisons across groups were made using
repeated measures analysis of variance (ANOVA) or Friedman test, depending on
whether data were normally distributed. Statistical significance was assumed at p <0.05.
Data were analysed using GraphPad Software (San Diego, CA).

3.4 Group Characteristics

Table 3.1 shows the anthropometric characteristics of the group, presented as
mean and standard deviation (SD). The age of the subjects ranged between the 52.7 ±
11.51 years in the control group, 63.5 ± 9.49 years in the COPD group and 61.9 ± 13.15
years in the ILD group. Forty three subjects never smoked (48%) in contrast with 47 exsmokers (52%), with a predictably higher number of ex-smokers in the COPD group
(100%). In the control group, 5 ex-smokers were identified and included in the study.
Despite of ex-smokers they presented normal lung function confirmed by spirometry,
normal DLcoSB measurements and no history of lung disease or respiratory problems.
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Parameter

Control (n=30)

COPD (n=30)

ILD (n=30)

Age (years)

53 ± 11.5

63.5 ± 9.5

62 ± 13

Sex (M/F)

14/16

24/6

18/12

BMI Kg/m²

27 ± 5

25.5 ± 3

26 ± 4

Hb (g/dL)

13 ± 0.5

13.7 ± 1.2

13.6 ± 1

Non/Ex-Smoker

25/5

0/30

18/12

Table 3.1. Group Characteristics. Values are mean ± SD (where applicable)

3.5 Spirometry measurements

In the control group, the mean FEV1 % predicted and FEV1/FVC ratio were
normal (Table 3.2).
In the severe COPD group, the mean FEV1 % predicted was 37.02 ± 7.92 and
FEV1/FVC ratio 47.0 ± 9.24, indicating severe airflow obstruction.
In the ILD group, the mean FVC % predicted was 69.3 ± 14.60 and FEV1/FVC
ratio 80.0 ± 10.88 showed a non-obstructive ventilatory defect. (Brusasco et al., 2005)
All the sarcoidosis patients in the ILD group were clinically and radiological classified
of stage two.
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Parameter

Control (n=30)

COPD (n=30)

ILD (n=30)

FEV1 (L)

3.2 ± 0.653

1.05 ± 0.257

1.90 ± 0.627

FEV1 % predicted

107.3 ± 12.04

37.02 ± 7.92

69.5 ± 17.61

FVC (L)

3.81 ± 0.798

2.27 ± 0583

2.37 ± 0.735

FVC % predicted

106.5 ± 11.78

63.1 ± 10.32

69.3 ± 14.60

FEV1/FVC %

83.5 ± 4.88

47.0 ± 9.24

80.0 ± 10.88

Table 3.2 Spirometry data by group. Values are mean ± SD

3.6 DLcoSB by the single breath method

All subjects were clearly instructed before and during testing by the same
certified respiratory scientist, and had no difficulty in achieving two reproducible
measurements to meet ATS/ERS criteria. (MacIntyre et al., 2005) The mean values for
DLcoSB, VA and KCO measured with a 10 s breath-hold are described in the Table 3.3.
Parameter/Group

Control (n=30)

COPD (n=30)

ILD (n=30)

DLcoSB, mmol/min/kPa

8.10 ± 1.446

3.42 ± 1.522

3.47 ± 1.351

DLcoSB % predicted

90.6 ± 8.07

39.8 ± 16.38

40.4 ± 13.02

VA (L)

5.44 ± 0.897

4.33 ± 1.137

3.56 ± 0857

VA % predicted

96.1 ± 10.10

73.9 ± 15.78

61.7 ± 12.38

KCO, mmol/min/kPa

1.48 ± 0.183

0.79 ± 0.360

0.97 ± 0.312

KCO % predicted

97.8 ± 10.96

57.6 ± 25.47

67.5 ± 18.07

Table 3.3. CO Diffusion measurement by the Single Breath method with 10 s breath-hold.
Values are mean ± SD
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All measurements in the control group were normal (Table 3.4). In the severe
COPD group, the DLcoSB % predicted was severely decreased (<40%) and in the ILD
group, moderate impairment was present (40-60%). (Brusaco et al., 2005)
The DLcoSB and DLcoSB % predicted measured in severe COPD and ILD
patients was very similar and differed significantly from values measured in the control
group. The group with ILD had the lowest VA and VA% predicted. The lowest KCO and
KCO % predicted were found in the severe COPD group.

3.7 DLcoSB measurement by the single breath method with breath-hold time
reduction

Each group performed the DLcoSB measurements at three different breath-hold
times always by the same order of 10, 8 and 6 s, not randomised, with similar inspired
and expired VC.
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Breath-Hold time
10 s

8s

6s

p value

DLcoSB mmol/min/kPa 8.10 ± 1.446

8.18 ± 1.428

8.02 ± 1.453

0.4431

DLcoSB % pred

90.6 ± 8.07

91.9 ± 10.35

89.8 ± 8.56

0.3943

KCO mmol/min/kPa

1.48 ± 0.183

1.51 ± 0.157

1.52 ± 0.208

0.1861

KCO % pred

97.8 ± 10.96

99.0 ± 9.15

99.3 ± 12.65

0.4369

DLcoSB mmol/min/kPa 3.42 ± 1.522

3.19 ± 1.387

2.96 ± 1.482

0.0003*

DLcoSB % pred

39.8 ± 16.38

37.3 ± 15.14

34.7 ± 16.91

0.0019*

KCO mmol/min/kPa

0.79 ± 0.360

0.75 ± 0.334

0.72 ± 0.360

0.0183*

KCO % pred

57.6 ± 25.47

55.3 ± 24.39

53.2 ± 26.41

0.0489*

DLcoSB mmol/min/kPa 3.47 ± 1.351

3.50 ± 1.342

3.44 ± 1.392

0.5915

DLcoSB % pred

40.4 ± 13.02

40.9 ± 12.84

40.1 ± 13.65

0.5251

KCO mmol/min/kPa

0.97 ± 0.312

0.99 ± 0.298

0.99 ± 0.310

0.4921

KCO % pred

67.5 ± 18.07

68.6 ± 16.31

68.2 ± 17.29

0.6177

Control (n=30)

COPD (n=30)

ILD ( n=30)

* Significance p<0.05
Table 3.4 DLcoSB measurements at different breath-hold time.
Values are mean ± SD.

In the control and ILD group, there were no significant differences in DLcoSB
and KCO measured using the three different breath-hold times 10, 8 and 6 s (p>0.05).
However, in patients with COPD, there was a significant difference in the DLcoSB and
KCO measurements across the 3 breath-hold times (p<0.05). As breath-hold time was
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reduced from 10 to 8 and 6 s, the DLcoSB and KCO in severe COPD patients decreased
gradually. The comparison of the DLcoSB and KCO measured in the three study groups
at different breath-hold times is illustrated by Figures 3.1 and 3.2.

10
DLcoSB
mmol/min/kPa

NS

DLcoSB
% pred

Normal

100

NS

Normal

0

0

10

100
p=0.0019

p=0.0003

COPD

COPD

0

0

10

100
NS

NS

ILD

ILD

0

0
10s

8s

10s

6s

8s

6s

Fig. 3.1
Comparison of DLcoSB at different breath-hold times across groups.
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2
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KCO
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100

Normal

0

0

2
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p=0.0489

p=0.0183

COPD

COPD

0

0

2

100

NS

NS
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0

0
10s

8s

10s

6s

8s
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Figure 3.2
Comparison of KCO at different breath-hold times across groups.

Analysing the DLcoSB measurements at different breath-hold times was
detected that in the severe COPD group, a significant difference in DLcoSB measured
and DLcoSB% predicted with reduction of breath-hold from 10 to 8 s, however there
was no significant difference detected in KCO measured from 10 to 8 s breath-hold time
also stated by MacIntyre et al. (2005) previous report.
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Breath-hold time
COPD

10 s

8s

p value

DLcoSB, mmol/min/kPa

3.42 ± 1.522

3.19 ± 1.387

0.0110*

DLcoSB % pred

39.8 ± 16.38

37.3 ± 15.14

0.0242*

KCO, mmol/min/kPa

0.79 ± 0.360

0.75 ± 0.334

0.0636

KCO % pred

57.6 ± 25.47

55.3 ± 24.39

0.1410

* Significant difference p<0.05
Table 3.5 – Diffusion capacity in patients with COPD after 10 and 8 s of breath-hold time.
Values are mean ± SD

Table 3.6 describes the effect of reduction in breath-hold time on measured VD
across the 3 groups. These measurements are relevant as VD is the air in conducting
airways and alveolar space that does not participate in the gas exchange and will
therefore produce changes in the DLcoSB measurement.
Breath-hold time

VD ml

10 s

8s

6s

p value

155.74 ± 7.681

155.3 ± 8.242

153.95 ± 8.628

0.0442*

161.42 ± 9.694

154.92 ± 7.822

155.58 ± 8.880

0.1563

164.25 ± 11.046

150.12 ± 28.588

155.57 ± 2.235

0.0434*

Control (n=30)
VD ml
COPD(n=30)
VD ml
IPF (n=30)
*Significant difference p<0.05
Table 3.6 Total dead space volume measured by the single breath method at different
breath-hold times. Values are mean ± SD
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The measured VD values at different breath-hold times were significantly
different in the control and IPF group but no significant difference was found in the
severe COPD group.
Also, as He is used as a tracer gas to determine the initial CO concentration and
measure VA in the single breath method by the dilution of He, the He and CO fraction
were measured at different breath-hold times and mean results compared, in order to
determine if the breath-hold time reduction will affect the fraction of He and CO in the
final sample analysed. The results are presented in table 3.7.
In the control and ILD groups, no significant difference was found in the FAHe
measured as breath-hold time reduced, but significant differences were seen in the
severe COPD group. Regarding the FAco, in all three groups studied there was a
significant difference with breath-hold time reduction, which increased as the breathhold time decreased in all study groups.
Breath-Hold time

Control (n=30)

COPD (n=30)

ILD (n=30)

10 s

8s

6s

p value

FAHe

5.62 ± 1.192

5.40 ± 1.533

5.86 ± 0.700

0.4437

FAco

0.099 ± 0.048

0.107 ± 0.048 0.113 ± 0.034

<0.0001*

FAHe

4.62 ± 0.801

4.78 ± 0.773

0.0090*

FAco

0.093 ± 0.018

0.104 ± 0.035 0.109 ± 0.018

<0.0001*

FAHe

5.16 ± 0.963

5.27 ± 0.828

0.1345

FAco

0.101 ± 0.036

0.106 ± 0.019 0.116 ± 0.019

4.78 ± 0.794

5.33 ± 0.835

<0.0001*

* Significance p<0.05
Table 3.7 FAHe and FAco measured by the single breath method with different breathhold time. Values are mean ± SD
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The VA measurement depends on He dilution during the single breath method
and also adjusts for the KCO calculation. Comparisons were made between the VA and
VA % predicted in the three study groups as breath-hold reduced and table 3.8 reports
the data obtained. There was no significant difference between the VA measured in all
study groups with breath-hold time reduction, except in the measured VA % predicted in
the COPD group as shown in figure 3.3, which significantly reduced with breath-hold
time reduction.
Breath-hold time

Control (n=30)

COPD (n=30)

ILD (n=30)

10 s

8s

6s

p value

VA

5.44 ± 0.897

5.43 ± 0.956

5.32 ± 0.928

0.1769

VA % pred

96.1 ± 10.10

96.0 ± 12.90

93.9 ± 10.43

0.2281

VA

4.33 ± 1.137

4.35 ± 0.786

4.19 ± 0.761

0.3114

VA % pred

73.9 ± 15.78

72.6 ± 14.18

70 ± 14.25

0.0107*

VA

3.56 ± 0.857

3.53 ± 0.858

3.47 ± 0.847

0.3050

VA % pred

61.7 ± 12.38

61.2 ± 12.88

60.2 ± 12.73

0.2499

* Significance p<0.05
Table 3.8 VA and VA% predicted measured by the single breath method with different
breath-hold time. Values are mean ± SD
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Chapter 4

DISCUSSION OF RESULTS

4.1 Anthropometric Data

Previously published studies (Magnussen et al., 1979; Graham et al., 1985;
Dressel et al., 2008) analysing the breath-hold time effect on DLcoSB measurement,
presented different subject demographics compared to the present study and also the
population age was younger when compared with the present study. The breath-hold
time effect on DLcoSB measurement in previous reports (Magnussen et al., 1979;
Graham et al., 1985; Dressel et al., 2008) was studied in patients with asthma,
emphysema and cystic fibrosis, contrasting with COPD and ILD in the present study.
The population size studied in the present study was also considerably larger than
previous studies (Magnussen et al., 1979; Graham et al., 1985; Dressel et al., 2008)
(Table 4.1).
Previous studies (Magnussen et al., 1979; Graham et al., 1985; Dressel et al.,
2008) have analyzed the effect of DLcoSB breath-hold reduction in healthy subjects and
patients with respiratory obstructive disorders, but not in non-obstructive pulmonary
disorders such as ILD. The BMI was not calculated in any of the previous studies
(Magnussen et al., 1979; Graham et al., 1985; Dressel et al., 2008) and may be relevant
in DLcoSB interpretation, as obesity, according to MacIntyre et al. (2005) increases the
θVc and thus increases the DLcoSB value. In the present study, the mean BMI was
increased in all 3 study groups, which may have led to a higher DLcoSB measured.
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Studies

Study Group/Age

BMI

(n=population number)

Sex

Non/Ex/Smoker

(M/F)

Magnussen et al., 1979

Normal 36.9

(n=47)

Emphysema 61.7

No data

No data

No data

No data

9/6

10/0/0

Asthma 47.1

Graham et al., 1985

Normal 35±15

(n=36)

Emphysema 54±11

8/2

1/6/3

Asthma 40±16

8/3

4/7/0

No data

14/6

20/0/0

Dressel et al., 2008

Normal 33±9

(n=20)

CF 31±9

Present Study 2012

Control 53±11.5

27±5

14/16

25/5/0

(n=90)

COPD 63.5±9.5

25.5±3

24/6

0/30/0

ILD 62±13

26±4

18/12

18/12/0

Table 4.1 Anthropometric data in 3 studies analysing the breath-hold time effect on the
CO diffusion measurement by the single breath method
Age in years, Body mass index in Kg/m2 (BMI), Sex (M/F = number of males and females in
study population), Non/Ex/Smoker = number of Non-smokers, ex-smokers and smokers in the
study population. Values are mean ± SD where applicable.

In the present study, 62% of subjects were males and 38% of females and in
previous studies (Magnussen et al., 1979; Graham et al., 1985; Dressel et al., 2008)
there was similar gender distribution of subjects studied.
Regarding the population smoking habits of the present study, 48% never
smoked in contrast with 52% ex-smokers, with a higher prevalence of ex-smokers on
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the COPD group (100%). Similar population smoking habits were reported by Graham
et al. (1985), despite the presence of three current smokers recruited in this study.
Active smoking was an exclusion criterion in the present study, as COHb decreases
DLco mainly due to the effects on CO back pressure and also decreasing the Hb binding
sites for CO test gas. (MacIntyre et al., 2005) None of the other previous studies
(Magnussen et al., 1979; Dressel et al., 2008) had smokers among the population.

4.2 Spirometry measurements

To identify and recruit the present study population, spirometry was performed
in order to determine normal, obstructive and non-obstructive ventilatory defects.
Spirometry was also performed in previous studies (Magnussen et al., 1979; Graham et
al., 1985; Dressel et al., 2008) to determine the FEV1 and FVC of the population (Table
4.2).
The degree of airflow obstruction present in our study population in the severe
COPD group may have been more severe when compared with previous studies
(Magnussen et al., 1979; Graham et al., 1985; Dressel et al., 2008). In Dressel et al.
(2008), the CF group had mild to moderate airway obstruction (Pellegrino et al., 2005)
and in Magnussen et al. (1979) and Graham et al. (1985), only the FEV1/FVC ratio was
reported. However, the FEV1/FVC ratios of these two study groups were similar to the
FEV1/FVC ratio of patients with severe COPD in the present study (Table 4.2).
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Study

Group

FEV1% pred

FVC% pred

(n=population number)

FEV1/FVC%
pred

Magnussen et al., 1979

Normal

No data

(n=47)

Emphysema

42.0±14.2

Asthma

46.6±14.1

No data

No data

No data

77.1±14.2

Graham et al., 1985

Normal

81±9

(n=36)

Emphysema

44±16

Asthma

54±7

Dressel et al., 2008

Normal

108±8

114±10

No data

(n=20)

CF

69±28

84±5

Present Study 2012

Control

107.3 ± 12.04

106.5± 11.78

83.5 ± 4.88

(n=90)

COPD

37.02 ± 7.92

63.1 ± 10.32

47.0 ± 9.24

ILD

69.5 ± 17.61

69.3 ± 14.60

80.0 ± 10.88

Table 4.2 Spirometry measurements in 3 studies analysing the breath-hold time effect on
the CO diffusion measurement by the single breath method. Values are mean ± SD;
n=number of subjects per group.

Another important variable to consider is the bronchodilator effect on
spirometric values measured, as well as on measured DLcoSB. In the present study, all
spirometry and DLcoSB measurements were performed after inhaled bronchodilator,
which may have led to a higher measured FEV1 and DLcoSB. Inversen et al. (1999)
reported that in obstructive lung diseases after bronchodilator administration, the DLco
may increase up to 6%. Similarly, Chinn et al. (1988) reported that bronchodilators may
affect VA and the vasomotor tone. In the Graham et al. study, all patients avoided
bronchodilators for at least 8 hours prior to testing. In the Dressel et al. (2008) study, no
mention was made of inhaled bronchodilator use by the study population.
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4.3 DLcoSB by the single breath method measurements

4.3.1 DLcoSB in the control group

The diffusion capacity is defined by Magnussen et al. (1979) as a conductance,
consisting of transport of a gas divided by its pressure gradient between alveolar gas
and capillary blood.
Jones & Meade (1979) suggested that the decrease of DLcoSB with increasing
breath-hold time, also reported in healthy subjects by Forster et al. (1954), will be less
significant if corrections for the time of breathing were applied, thus allowing a better
estimate of the alveolar-capillary diffusion barrier. No such corrections were made in
the current study as was aimed to detect from DLcoSB measurements the resistance to
diffusion across the alveolar capillary membrane and the influence of respiratory
disorders on these measurements.
The DLco in the present study was measured by the single-breath method of
Ogilvie et al. (1957) modified by Jones and Meade (1961). The VA was measured
during the single breath measurement from the dilution of He according to McGrath and
Thomson (1959). The values obtained for the DLcoSB in the control group did not
change with reductions of breath-hold time, as no significant differences were found
between DLcoSB and KCO measured at 10, 8 and 6 s (p>0.05). These results were
consistent with Graham’s previous study (Graham et al., 1985), which reported no
significant difference (p>0.05) in DLcoSB values measured in healthy subjects at
different breath-hold times (10, 5 and 2 s). On the other hand, other previous studies
(Jones and Meade, 1961; Graham et al., 1980; Graham et al., 1981; Graham et al.,
1984) reported that DLcoSB increases during short and long breath-hold periods in
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healthy subjects. Graham et al. (1985) used the three-equation calculation method for
DLcoSB measurement, which differs from the conventional single Krogh equation used
in the present study and all other studies previously mentioned (Magnussen et al., 1979;
Dressel et al., 2008). Despite of different calculation methods, the results for DLcoSB
measurements were similar in Graham et al. (1985) and the current study. Graham et al.
(1985) justified the conflicted results for DLcoSB measured obtained with other
previous studies, with the calculation method used (the three equation method), arguing
that the increase in DLcoSB with short/long breath-hold times using the conventional
single equation method in normal subjects will ignore CO uptake during inhalation and
exhalation phases of the single breath manoeuvre, increasing errors as breath-hold time
becomes shorter. The DLcoSB rise, according to Graham et al. (1985), may be
explained by the inefficiency of the method rather than any impairment in lung
diffusion. MacIntyre at al. (2005) suggests in the ATS/ERS statement that the threeequation method can improve the accuracy of DLcoSB measurement, as it allows for
volumes changes over time during inspiration and expiration when a measurement is
being performed. This method might be more useful in subjects unable to rapidly inspire
or expire rather than in healthy subjects. Despite the advantages of this calculation
method, clinical experience with this approach is limited and need further
standardization.
The DLcoSB results of the control group in the present study (with considerably
more subjects when compared to Graham et al. (1985) study), demonstrated no change
in measured DLcoSB associated with breath-hold time reduction by the conventional
single equation calculation method, suggesting that both methods may be suitable for
DLcoSB assessment. The single equation method for DLcoSB calculation was also used
in the other two previous studies (Magnussen et al.,1979 and Dressel et al., 2008),
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where DLcoSB was reported to decrease with increasing breath-hold time in 14 healthy
subjects (Magnussen et al., 1979) and in 10 healthy subjects (Dressel et al., 2008).
Dressel et al. (2008) also observed a significant difference between the DLcoSB
measured at 4, 6, 8 and 10 s in healthy subjects (p<0.05), however similarly to the
present study, no significant difference was identified between the DLcoSB measured at
8 and 6 s. The Magnussen et al. (1979) study measured DLcoSB at 10, 8, 6, 4 and 2 s
and only reported a significant difference for DLcoSB measurements when breath-hold
time was reduced to 6, 4 and 2 s in all groups, and in the emphysema group at 8 and 6 s.
No significant effects were seen in DLcoSB measured at 10, 8 and 6 s for the healthy
and asthma group.
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Fig. 4.1
DLcoSB measurement in 4 studies analysing the breath-hold time effect on DLcoSB
measurements with different breath-hold times.
Closed circles joined by solid lines represent DLcoSB mean measured different breath-hold
times. Square brackets and p value indicate significant differences within DLcoSB values
measured at different breath-hold times using two-tailed paired t test.

These data strongly suggest that the breath-hold time for DLcoSB measurement
could be reduced to 8 or 6 s as standard for healthy subjects, and still produce reliable,
feasible and valid DLcoSB values.
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4.3.2 DLcoSB measurement in obstructive and non-obstructive pulmonary
disorders

The diffusion capacity of the lung for a gas is directly proportionate to the size
of the alveolar capillary membrane and inversely proportionate to its thickness. Any
process that decreases the surface available for diffusion or thickens the alveolarcapillary membrane will decrease the DLco.
In obstructive pulmonary disorders such as COPD lung volumes are increased
by air trapping with consequent hyperinflation, the alveolar walls and capillaries are
typically destroyed reducing the total surface area available for gas exchange in the
lung. According to MacIntyre et al., (2005), the CO during DLcoSB measurement may
only reach better ventilated regions of the lung and therefore the measured CO uptake
will be determined predominantly by the capacity of those regions. On the other hand,
in asthma (West, 2008b), the DLcoSB is reported to be normal or increased possibly due
to a more uniform distribution of the pulmonary blood flow. (Hyatt et al., 2003)
In the severe COPD group of the present study, there were significant
differences in the DLcoSB and KCO (p<0.05) measured at 10, 8 and 6 s of breath-hold,
suggesting a correlation of the DLcoSB with breath-hold time reduction when severe
airway obstruction is present. Analysis of results indicated that less than 10 s of breathhold time was insufficient to allow complete diffusion of inspired CO. This might be
explained either by the alveolar destruction present in this disorder decreasing the
surface area for diffusion or by air trapping preventing complete CO washout. A
significant difference between the DLcoSB measurement at 10 and 8 s was also noted;
however, there was no significant change in KCO.
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Dressel et al. (2008) demonstrated no influence of breath-hold time on DLcoSB
in 10 patients with CF (figure 4.1). In contrast, Graham et al. (1985) found that DLcoSB
decreased with breath-hold time reduction in patients with asthma and emphysema. The
authors explained this finding by suggesting stratification of inhaled gas within the gasexchanging lung regions prior to the effective alveolar-capillary gas exchange.
Equilibration of inspired and alveolar gas might take longer when airflow obstruction is
present. (Chang et al., 1973) The longer time needed for complete mixing of CO with
alveolar air may cause a reduction in measured DLcoSB when airflow obstruction is
present. The results obtained by Graham et al. (1985) are similar to the results obtained
in the present study for patients with severe COPD, despite of the different calculation
method used for DLcoSB. Graham et al., (1985) also reported that a lower DLcoSB at
shorter breath-hold time when airway obstruction is present, may lead to higher
resistance to gas exchange due to a longer path that the inspired gas has to diffuse to
reach the alveolar-capillary membrane.
Magnussen et al. (1979) similarly observed that DLcoSB decreased with breathhold time reduction in patients with emphysema; however in patients with asthma, the
DLcoSB results were comparable to normal subjects and increased with the breath-hold
time reduction. Magnussen et al. (1979) suggested that the reduction of DLcoSB with
lower breath-hold time in airway obstruction may be due to loss of gas exchange area
but also to stratification of the gases mixing in the lung. Sikand et al. (1976) and
Kawashiro et al. (1976) also suggested that gradients of intrapulmonary gas
concentration are better explained by the stratified inhomogeneity present in the lungs.
Magnussen et al. (1976) and Nieding et al. (1978) demonstrated that in patients with
emphysema, stratification is an important factor limiting intrapulmonary gas mixing. As
emphysema is a key feature of COPD, can also be inferred that the decreased DLcoSB
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in the present study with breath-hold time reduction in the severe COPD group, may be
due to poor He and CO intrapulmonary mixing limited by stratification.
All subjects in the present study population were non-smokers or ex-smokers,
which minimized the “CO back pressure” influence in DLcoSB measurements.
According to Qutayba et al. (2005), COHb exists in small concentrations, around 1% in
non-smokers but increases with repeated DLcoSB measurements, up to 10% or higher
in chronic smokers. If DLcoSB is not adjusted for the COHb increase, the so-called
“anaemia effect” can occur, reducing the effective Hb available to bind with CO in the
test gas mixture, leading to DLcoSB underestimation. The DLcoSB measured can be
underestimated if COHb is not adjusted for the ambient alveolar CO concentration
before each single breath measurement, which is assumed to be zero but is increased in
smokers according to Graham et al. (2002). Abstinence from cigarette smoking 24
hours prior to DLcoSB testing can help to reduce COHb and consequent CO backpressure (MacIntyre et al., 2005). In the present study, all subjects were non-smokers or
ex-smokers, which eliminated the effect of CO back pressure and the need for COHb
correction during DLcoSB measurement.
To summarise the results of our study and previous studies in relation to COPD,
the breath-hold time for DLcoSB measurement in patients with COPD should be
retained at 10 s and certainly should not be reduced to less than 8 s.
The main reason to assess the effect of breath-hold time reduction on measured
DLcoSB in patients with ILD was the absence of published data in this clinical context.
We decided to study patients with sarcoidosis with pulmonary fibrosis and patients with
IPF to evaluate the effect of the breath-hold time reduction when thickening of the
alveolar-capillary membrane is present.
In the ILD group, no significant difference was observed in DLcoSB and KCO
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measured at 10, 8 and 6 s (p>0.05), despite the expected baseline reduction of DLcoSB.
The mean DLcoSB % of predicted was 40.4 ± 13.02 for 10 s of breath-hold in the ILD
group, indicating a moderate to severe impairment of diffusing capacity according to
ATS/ERS criteria. Despite of a similar impairment degree of DLcoSB in patients with
ILD compared with the severe COPD group, there was no significant difference
between the DLcoSB and KCO measured at 10, 8 and 6 s in the ILD group. From the 30
patients of the ILD group, 15 were clinically diagnosed stage two sarcoidosis patients
with radiologic hilar adenopathy and parenchymal infiltration reflecting a nonobstructive ventilatory defect on spirometry measurements (table 3.2) and also moderate
impairment was present when DLcoSB and KCO were measured (40-60%). (Brusaco et
al., 2005)
Roughton and Forster (1957) reported that the resistance to diffusion of a gas in
the lung will depend of the resistance offered by the alveolar-capillary membrane to the
gas transferred and also on the resistance of the chemical combination with Hb. In other
words, the resistance to diffusion of CO in the lung will depend of the features of the
alveolar-capillary membrane and the quantity of Hb in the pulmonary capillaries
available to combine with CO. Therefore, the DLco measured will depend of membrane
factors and circulatory factors. According to Weinberger et al. (1980) the alveolarcapillary membrane can be quantitatively impaired referring to the surface area per lung
volume, and qualitatively impaired, referring to a change in the membrane thickness. In
ILD, thickening of the alveolar wall will increase the resistance to diffusion of gas
across the alveolar-capillary membrane. However, Weinberger et al. (1980) reported
that the relative contribution of the membrane thickness in lowering the DLco in
disorders such as interstitial fibrosis may be overestimated. Other pathological changes,
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like alteration of alveolar architecture, can reduce the alveolar-capillary membrane
surface area for gas exchange, which appears to be more relevant to reductions in DLco.
When breath-hold time was reduced from 10 to 8 and 6 s, no significant
difference was observe in measured DLcoSB as shown in figure 3.1. These results
suggested that despite of quantitative and qualitative changes in the alveolar-capillary
membrane in patients with ILD, breath-hold time reduction will not produce significant
changes in the DLcoSB measured, similarly to the control group already discussed.
McNeill et al. (1958) reported that in pulmonary fibrosis due to sarcoidosis, the
membrane component (DM) is significantly more reduced than capillary volume and
Johnson et al. (1961) observed that the reduction of DM was the major change and Vc
was relatively unaffected. According to Hamer (1963), the reduction in DM after several
years of pulmonary infiltration may be due to fibrotic changes reducing the area
available for diffusion and Vc reduction is only commonly observed in patients with
prolonged disease. Reduction of the Vc was not observed without DM reduction, which
suggests that Vc changes are more frequently associated with increased severity of
fibrosis. Additionally, Marshall et al. (1958) suggested that in pulmonary sarcoidosis,
diffusion changes are mainly due to perivascular lesions rather than relative changes in
the mechanical properties of the lungs.
The loss of the alveolar-capillary membrane surface area in patients with COPD
through destruction of alveolar walls when compared with the loss of alveolar-capillary
membrane surface area in patients with ILD through scarring and thickening of the
alveoli, seemed to generate more significant changes in DLcoSB measurement with
reduced breath-hold time. This suggests that airflow obstruction may be more
responsible for decrease of the DLcoSB measured with breath-hold time reduction.

111

Krogh (1915) originally reported that the DLco decreased with VA reduction
until FRC was reached and the progressive decrease in the size of the membrane would
explain this change. Other studies (Ferris, 1978) have confirmed Krogh’s observation
and similarly noted that changes in VA are responsible for DLco measurement
variability. Forster Farhi, L. Tenney, S. (1987) suggested that: “If the normal lung was a
collection of spheres and if DLcoSB was directly proportional to the surface area of the
spheres, then DLcoSB would vary with alveolar volume”. In contrast, Cotton and
Qutayba et al., (2005) suggested that the capillary surface area is preserved with a
decreased VA, as the alveolar-capillary membrane tends to fold, rather than shrink,
when lung volume decrease.
In the present study, the VA measured by He dilution during breath-hold in the
DLcoSB measurement was reduced in patients with severe COPD and ILD, with a
higher reduction in patients with ILD. As breath-hold time was reduced in DLcoSB
measurements from 10 to 8 and 6 s, no significant difference was observed in VA
measured in all study groups, except in the measured VA % predicted in the severe
COPD group. According to Fishman in Farhi and Tenney (1987), the resistance of the
vascular alveolar segment decreases with VA reduction from TLC to FRC, while
pulmonary capillaries widen and Vc increases. Graham et al., (2002) reported that a VA
reduction from TLC to 50% of IC will decrease DLcoSB minimally. Fishman (2007)
states that DLco decreases with reduction of VA along with the reduction of available
surface area and Vc for diffusion. The idea from Fishman in Farhi and Tenney (1987)
that the Vc may increase with VA reduction while the capillary bed is still preserved
may help to understand why in the present study, even with a low VA in the ILD group,
the breath-hold time reduction did not produce significant changes in measured
DLcoSB and KCO (p<0.05). This might suggest that 6 s of breath-hold time can be as
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valid as 10 s to measure DLcoSB in patients with ILD, in the absence of concomitant
airflow obstruction.
During the single breath method to measure DLco, after breath-hold and during
expiration, the first 750 ml of volume is discarded and the next 750 ml of gas is used for
analysis. In the severe COPD group in the present study, due to low VC (<2L) only 500
ml was collected for sampling. (MacIntyre et al., 2005) The first 750 ml of expired
breath contains gas from the anatomical VD (volume in the conducting airways that does
not participate in gas exchange) and instrumental VD (mouthpiece, filters and
connections of the system). (MacIntyre et al., 2005) As VD corresponds to the portion of
expired volume in the DLcoSB measurement that does not participate effectively in gas
exchange during breath-hold, was decided to investigate if the measurement of VD was
affected by the breath-hold time reduction.
Therefore, VD was measured at different breath-hold times (10, 8 and 6s) and
results are presented in Table 3.6. Significant differences were found in the control and
ILD groups when breath-hold time was reduced. However, no significant difference was
found in the VD measured in the severe COPD group.
According to Morton et al., (1965) the alveolar gas sample, when contaminated
by VD gas, may lead to CO uptake underestimation. Was observed that in the control
group and patients with ILD, breath-hold time reduction led to a significantly reduced
VD (p<0.05) however the measured DLcoSB and KCO were not affected. Therefore, the
effect on VD was not significant. On the other hand, no significant difference was found
in the severe COPD group for the VD measured at different breath-hold time and yet,
significant differences were detected in the measured DLcoSB and KCO with breathhold time reduction.
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Morton et al. (1965) stated that the initial and final CO concentrations in
DLcoSB measurement are affected by dead space washout, as initial CO is determined
by the dilution of He. If dead space is not efficiently washed out, the final concentration
of He in the expired sample will be higher and lead to higher initial CO concentration.
Morton et al. (1965) observed patients with normal and impaired alveolar gas
distribution and noted that differences in expired volumes led to less dilution of dead
space He and CO. He also noted that the size of the expired sample could have been
reduced by air trapping since subjects with uneven alveolar ventilation had severe
obstructive airways disease. Based on these data, it is not clear whether the time for
complete washout of He and CO in the severe COPD group was sufficient to provide
complete elimination of the gas mixture in the alveolar space between measurements
and thus avoid changes in measured DLcoSB.
The table 3.7 shows that there were significant differences (p<0.05) in the FAHe
and FAco alveolar fraction measured with breath-hold time reduction from 10 to 8 and 6
s in the severe COPD group, as reported by Morton et al. (1965). This might have been
a significant factor accounting for the reduction in measured DLcoSB at progressively
reduced breath-hold time in patients with severe COPD. However, in the control and
ILD groups no significant difference was found for the FAHe measured, despite of a
similar FAco difference. This results indicated that the time between measurements for
the He washout from the alveolar space for the control and ILD group was adequate, as
per ATS/ERS guidelines (MacIntyre et al., 2005) 4 minutes between manoeuvres and 1
hour between measurements. In the severe COPD group, the time recommended of 10
minutes in between DLcoSB manoeuvres and 1 hour in between measurements may not
to be sufficient for He and CO alveolar washout as significant differences were found.
This might suggest that time in between measurements should be extended when severe
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airflow obstruction is present, as the expired sample is reduced by air trapping in
COPD, prolonging the test gas mixture washout and interfering with the DLcoSB
measured. (Hyatt et al., 2003)
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Chapter 5

CONCLUSION

5.1 Conclusions / Recommendations

The present study is the largest report analysing the effect of breath-hold time on
measured DLco measurement by the single breath method to date. Furthermore, our
data show some conflicting results when compared to previously published reports
(Magnussen et al., 1979; Graham et al., 1985; Dressel et al., 2008)
The present study indicates that in healthy subjects, measured DLcoSB and
KCO is not affected with breath-hold time reduction, as has been previously reported by
Magnussen et al. (1979) and Graham et al. (1985). However, in the presence of severe
COPD, the DLcoSB is influenced by breath-hold time, where DLcoSB and KCO
significantly decrease with breath-hold time reduction. These data leaded to conclude
that in patients with airflow obstruction, the time necessary for mixing of inspired gas
with alveolar gas will reduce the CO uptake when breath-hold time was decreased from
10 s, as suggested by the ATS/ERS guidelines (MacIntyre et al., 2005).
In contrast, in patients with ILD, despite moderate to severe baseline DLcoSB
impairment, there was no significant influence of breath-hold time reduction on
measured DLcoSB, suggesting that in patients with ILD who are unable to breath-hold
for 10 s, DLcoSB measurement using a 6 second breath-hold time may provide an
acceptable and clinically meaningful result.
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Was also conclude that the washout time, necessary to clear He and CO inhaled
in each DLcoSB measurement, is of major importance to produce valid results, as
impaired clearance of these gases from the alveolar space will interfere with the final
results for measured DLcoSB.
Can be useful further studies involving the population size increase of each
analysed group to determine whether results remain consistent, studying also the effect
of breath-hold time reduction on measured DLcoSB in patients with other types of ILD,
as well as, the effect of breath-hold time reduction on measured DLcoSB in patients
with different COPD stages. Also assess the dyspnoea degree of the study population
using the Borg Scale at the time of the DLcoSB measurements can provide useful
information. Furthermore, arterial blood gases assessment in addition to DLcoSB
measurements in patients with obstructive and non-obstructive ventilatory disorders
could help to assess ventilation/perfusion mismatching and its influence on DLcoSB
measurements. Day to day variability of the DLcoSB measurements should as well be
considered in further studies.

5.2 Publications

An abstract for this work has been accepted for poster discussion at the
European Respiratory Society meeting and was presented in Vienna on September 2012.
Abstracts will be submitted to the Irish Thoracic Society (2012) and American Thoracic
Society (2013) meetings and we hope to submit a manuscript to a peer-reviewed journal
for publication, after review of the thesis.
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Appendices

Appendix A
JAEGER MASTERSCREEN PFT



Power supply
Input range 230V, 50/60 Hz, 1.8 A



Dimensions
Length*Width*Height: 78 cm * 100 cm * 155 cm



Technical data

Flow measurement JAEGER pneumotacograph
Range 0 ± 20 l/s
Accuracy 0.2 - 12 l/s ± 2%
Resistance <0.05kPa/(l/s) at 10l/s

Volume determination digital integration
Range 0- ± 20 l
Accuracy 5 ml

Mouth pressure piezo-resistive
Range ± 20 kPa
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Accuracy < ± 2 %

CO analyser electrochemical cell
Range 0 - 0.4 %
Accuracy 0.0003 %

He analyser thermal conductivity
Range 0 - 9.5 %
Accuracy 0.05 %
Calibration CAL-Pack, automatically



Premixed gas
Diff-SB and Diff-RB 0.28 % CO, 9 % He, 19 % O2, Balance N2



Computer
Pentium computer, printer and monitor on an ergonomic, smoothly-running
trolley. Lab Manager Software version 5.3.0.4
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Appendix B
HEMOCUE HB 201+



Parameters recorded
Hb g/L



Performance Hb
Measuring Range: 0-256 g/L



Dimensions (HxWxD)
85x160x43 mm



Weight
350 gr



Power supply
4 Batteries type AA 0r R6, 1.5 V



Environmental conditions
Operating temperature: 15-300C
Analyser Storage Temperature: 0-500C
Microcuvettes Storage Temperature: 15-300C
Relative Humidity: should not be operated at high humidty (i.e.>90% noncondensing)
127

Appendix C
UNIVERSITY COLLEGE CORK

CONSENT BY SUBJECT FOR PARTICIPATION IN RESEARCH PROTOCOL

Section A
Protocol Number: ____________________ Patient Name: _________________

Title of Protocol: Effect of reduction of breath-holding time in the single-breath
method to assess carbon monoxide diffusing capacity.

Doctor Directing Research: Dr. Terry O’Connor, Mercy University Hospital, Cork
Phone: 021-4935325

You are being asked to participate in a research study. The doctors at University
College Cork study the nature of disease and attempt to develop improved methods of
diagnosis and treatment. In order to decide whether or not you want to be a part of this
research study, you should understand enough about its risks and benefits to make an
informed judgment. This process is known as informed consent. This consent form
gives detailed information about the research study, which will be discussed with you.
Once you understand the study, you will be asked to sign this form if you wish to
participate.

Section B
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I. NATURE AND DURATION OF PROCEDURE(S):

This study aims to investigate alternative ways of performing a test that we use
to assess your lung function. During this test, you are asked to perform spirometry and
CO-Diffusion which measure the lung volumes and gas exchange. CO-Diffusion
requires that you empty all the air in your lung and take a deep breath during which a
small amount of carbon monoxide will be inspired. When your lung is full you will
have to hold your breath for 10 s followed by a complete expiration. This procedure is
part of our routine assessment of lung function and is performed routinely
irrespective of your participation in the study. The additional testing that follows is
the study part of the assessment. After 1 hour of rest you will be asked to repeat the
CO-Diffusion test but holding your breath for 8 s, followed again by 1 hour of rest until
the last measure with 6 s of breath-holding. This test will be conducted in the
Respiratory Laboratory of the Mercy University Hospital and by a qualified Senior
Respiratory technician also involved in this study. All records involving your
participation in this research will be kept in complete confidentiality.

II. POTENTIAL RISKS AND BENEFITS:

All the measurements involved in this study are part of the clinical respiratory
assessment routinely conducted by the respiratory team. The amount of carbon
monoxide inspired during the measurements will be according with the American
Thoracic Society and the European Respiratory Society guidelines minimizing any risk
of injury to patients. This research may influence future guidelines for the performance
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of the CO Diffusion test and may reduce the breath-holding time required to perform
this test.

III. POSSIBLE ALTERNATIVES:

You may choose not to participate in this research protocol or withdraw from the
study at any time after consenting to participate. You will be given a copy of the consent
form for your records.

Section C

AGREEMENT TO CONSENT

The research project and the treatment procedures associated with it have been
fully explained to me. All experimental procedures have been identified and no
guarantee has been given about the possible results. I have had the opportunity to ask
questions concerning any and all aspects of the project and any procedures involved. I
am aware that participation is voluntary and that I may withdraw my consent at any
time. I am aware that my decision not to participate or to withdraw will not restrict my
access to health care services normally available to me. Confidentiality of records
concerning my involvement in this project will be maintained in an appropriate manner.
When required by law, the records of this research may be reviewed by government
agencies and sponsors of the research.

I, the undersigned, hereby consent to participate as a subject in the above
described project conducted at the Cork Teaching Hospitals. I have received a copy of
this consent form for my records. I understand that if I have any questions concerning
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this research, I can contact the doctor(s) listed above. If I have further queries
concerning my rights in connection with the research, I can contact the Clinical
Research Ethics Committee of the Cork Teaching Hospitals, Lancaster Hall, 6 Little
Hanover Street, Cork.

After reading the entire consent form, if you have no further questions about
giving consent, please sign where indicated.

Doctor:
Signature of Subject:

Witness:

Date:

Time: __________
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